



(51) International Patent Classification:

C07D 239/49 (2006.01) *A61K 31/505* (2006.01)
C07D 401/12 (2006.01) *A61K 31/5377* (2006.01)
C07D 403/12 (2006.01) *A61P 35/00* (2006.01)
C07D 413/12 (2006.01)

(21) International Application Number:

PCT/GB2010/050825

(22) International Filing Date:

20 May 2010 (20.05.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/180,238 21 May 2009 (21.05.2009) US

(71) Applicants (for all designated States except MG, US):

ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE). DAINIPPON SUMITOMO PHARMA CO., LTD [JP/JP]; 2-6-8 Dosco-machi 2 chome, Chuo-ku, Osaka 5418524 (JP).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED

[GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BENNETT,

Nicholas, James [GB/GB]; AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). MCINALLY, Thomas [GB/GB]; AstraZeneca R&D Charnwood, Bakewell Road, Loughbor-

ough, Leicestershire LE11 5RH (GB). THOM, Stephen [GB/GB]; AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).

(74) Agent: ASTRAZENECA INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES



(57) Abstract: The invention concerns compounds of Formula (I): wherein L^1 , R^1 , R^2 , R^3 , R^4 and X are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.

NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES

Field of the Invention

The present invention relates to novel pyrimidine derivatives and, more particularly, to novel pyrimidine derivatives that act as TLR7 agonists. This invention also relates to methods for the preparation of such pyrimidine derivatives and novel intermediates in the preparation thereof, to pharmaceutical compositions containing such pyrimidine derivatives, to the use of such pyrimidine derivatives in the preparation of medicaments, and to the use of such pyrimidine derivatives in the treatment of conditions mediated by TLR7, such as allergic diseases, autoimmune diseases, viral diseases and, in particular, cancer.

Background of the Invention

Toll-like receptors (TLRs) are expressed on a variety of immune cells, including macrophages and dendritic cells (DCs). TLRs recognise molecular motifs on pathogens called pathogen-associated molecular patterns (PAMPs) (1). To date, 13 TLRs have been identified in man, these include TLRs 1, 2, 4, 5 and 6, which are confined to the cell surface and TLRs 3, 7, 8 and 9 which are expressed in endosomes. Different TLRs recognise different pathogen-derived ligands, for example TLRs 2 (bacterial lipoproteins), 3 (double-stranded RNA/poly (I:C)), 4 (lipopolysaccharides), 5 (flagellin), 7 (single-stranded RNA) and 9 (CpG-containing DNA) (2). Ligation of TLRs on antigen-presenting cells, such as DCs, leads to production of proinflammatory cytokines, DC maturation and priming of the adaptive immune system (3). TLR7 and TLR9 are expressed by plasmacytoid dendritic cells (pDCs) and ligand recognition leads to the secretion of interferon- α (INF- α) (4). Preclinical studies investigating the effects of activation of TLRs, using bacterial or viral components, dosed as monotherapy and/or combined with anti-tumor agents, have shown tumour growth inhibition in a variety of murine tumour models (5).

Several small molecule TLR7 agonists have been described, including the imidazoquinoline, imiquimod, which has been used to treat a number of dermatological conditions e.g. genital warts, molluscum contagiosum and melanoma. In the case of melanoma, topically applied imiquimod (Aldara, Graceway Pharmaceuticals, Bristol, TN) demonstrated therapeutic responses in cutaneous metastatic melanoma and lentigo maligna

(6) and has been approved for the treatment of superficial basal cell carcinoma (BCC) (7). Preclinical and clinical studies indicate that imiquimod is likely to function through the induction of type 1 IFN and IFN-inducible genes, which in turn can have direct effects on tumour cell growth and/or harness components of the adaptive immune system (6, 7).


5 852A is another imidazoquinoline, which unlike imiquimod, is suitable for systemic administration. Currently 852A is in phase II clinical trials in a number of cancer indications, including melanoma (8).

Nevertheless, there remains a need for further TLR7 agonists which are more effective in the treatment of disease, for example cancer, by reason of their superior
10 potency and/or advantageous physical properties (for example, higher permeability, and/or lower plasma protein binding) and/or favourable toxicity profiles and/or favourable metabolic profiles in comparison with other known TLR7 agonists, for example 852A.

As now demonstrated herein, the pyrimidine derivatives of the present invention are capable of activating TLR7 *in vitro*. As a consequence of this activity, the pyrimidine
15 derivatives of the present invention are expected to have value in the prevention or treatment of human disease, for example cancer, either as a monotherapy or in combination with other chemotherapeutic agents or radiotherapy regimens.

Summary of the Invention

According to a first aspect of the present invention, there is therefore provided a
20 compound of Formula (I), or a pharmaceutically acceptable salt thereof:



wherein:

X represents $-\text{CH}_2-$, $-\text{NR}^8-$, $-\text{O}-$ or $-\text{S}(\text{O})_n-$;

25 **R¹** represents $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkoxy}$, $\text{C}_{1-6}\text{alkoxyC}_{1-6}\text{alkyl}$, $\text{hydroxyC}_{1-6}\text{alkyl}$, $\text{hydroxyC}_{1-6}\text{alkoxy}$ or $\text{hydroxyC}_{1-6}\text{alkoxyC}_{1-6}\text{alkyl}$;

R^2 represents hydrogen, C_{1-6} alkyl or phenyl wherein said phenyl is optionally substituted with 1, 2 or 3 substituents selected from R^6 ;

R^3 represents C_{1-6} alkyl, C_{1-6} alkoxy or $-S-C_{1-6}$ alkyl;

R^4 represents hydrogen, halogen, C_{1-6} alkyl or C_{1-6} alkoxy;

5 L^1 represents a direct bond, $-(CR^9R^{10})_m-$, $-CH=CH-(CR^9R^{10})_q-$, $-C\equiv C-(CR^9R^{10})_q-$, $-O-(CR^9R^{10})_q-$, $-C(O)-O-(CR^9R^{10})_q-$ or $-O-(CH_2)_q-NR^8-(CH_2)_q-$;

R^5 represents methyl, hydroxy, $-NR^{11}R^{12}$, C_{3-6} cycloalkyl, phenyl or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and heterocyclic rings are optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

R^6 represents C_{1-6} alkyl, fluoro C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, halogen, cyano, $-S(O)_n-C_{1-6}$ alkyl or $-CH_2-C(O)-O-C_{1-6}$ alkyl;

R^7 represents C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, hydroxy, hydroxy C_{1-6} alkyl or $-(CH_2)_q-NR^{11}R^{12}$;

15 R^8 represents hydrogen or C_{1-6} alkyl;

R^9 and R^{10} , identically or differently on each occurrence, represents hydrogen or methyl;

R^{11} and R^{12} independently represent hydrogen, C_{1-4} alkyl or C_{1-4} alkoxy C_{2-4} alkyl;

m represents 1, 2, 3, 4, 5 or 6;

n represents 0, 1 or 2; and

20 q , independently, represents 0, 1, 2, 3, 4, 5 or 6;

with the proviso that the compound of Formula (I) is other than:

[3-(2-amino-4-methyl-6-pentylamino-pyrimidin-5-ylmethyl)]-benzoic acid ethyl ester;

[3-(2-amino-4-methyl-6-pentylamino-pyrimidin-5-ylmethyl)-phenyl]-methanol;

methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxybenzoate;

25 (4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxyphenyl)methanol;

methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-fluorobenzoate;

(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-fluorophenyl)methanol;

or (4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-ylmethyl)phenyl)methanol.

30 In one embodiment there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein:

X represents $-\text{CH}_2-$, $-\text{NR}^8-$, $-\text{O}-$ or $-\text{S}(\text{O})_n-$;

R¹ represents C_{1-6} alkyl, C_{2-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy or hydroxy C_{1-6} alkoxy C_{1-6} alkyl;

R² represents hydrogen, C_{1-6} alkyl or phenyl wherein said phenyl is optionally substituted with 1, 2 or 3 substituents selected from **R⁶**;

R³ represents C_{1-6} alkyl, C_{1-6} alkoxy or $-\text{S}-\text{C}_{1-6}$ alkyl;

R⁴ represents hydrogen, halogen, C_{1-6} alkyl or C_{1-6} alkoxy;

L¹ represents a direct bond, $-(\text{CR}^9\text{R}^{10})_m-$, $-\text{CH}=\text{CH}-(\text{CR}^9\text{R}^{10})_q-$, $-\text{C}\equiv\text{C}-(\text{CR}^9\text{R}^{10})_q-$, $-\text{O}-(\text{CR}^9\text{R}^{10})_q-$, $-\text{C}(\text{O})-\text{O}-(\text{CR}^9\text{R}^{10})_q-$ or $-\text{O}-(\text{CH}_2)_q-\text{NR}^8-(\text{CH}_2)_q-$;

R⁵ represents methyl, hydroxy, $-\text{NR}^{11}\text{R}^{12}$, C_{3-6} cycloalkyl, phenyl or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and heterocyclic rings are optionally substituted with 1, 2 or 3 substituents selected from **R⁷**;

R⁶ represents C_{1-6} alkyl, fluoro C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, halogen, cyano, $-\text{S}(\text{O})_n-\text{C}_{1-6}$ alkyl or $-\text{CH}_2-\text{C}(\text{O})-\text{O}-\text{C}_{1-6}$ alkyl;

R⁷ represents C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, hydroxy, hydroxy C_{1-6} alkyl or $-(\text{CH}_2)_q-\text{NR}^{11}\text{R}^{12}$;

R⁸ represents hydrogen or C_{1-6} alkyl;

R⁹ and **R¹⁰**, identically or differently on each occurrence, represents hydrogen or methyl;

R¹¹ and **R¹²** independently represent hydrogen, C_{1-4} alkyl or C_{1-4} alkoxy C_{2-4} alkyl;

m represents 1, 2, 3, 4, 5 or 6;

n represents 0, 1 or 2; and

q represents 0, 1, 2, 3, 4, 5 or 6;

with the proviso that the compound of Formula **(I)** is other than:

[3-(2-amino-4-methyl-6-pentylamino-pyrimidin-5-yl)methyl]-benzoic acid ethyl ester;
methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxybenzoate;
or
methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-fluorobenzoate.

It is to be understood that any suitable **R⁴** and **L¹-R⁵** group of Formula **(I)** may be bonded to any available carbon atom of the phenyl ring, but not to the same carbon atom, and that **R⁵** may be linked to the phenyl ring *via* any suitable linker selected from **L¹**.

It is to be understood that, insofar as certain of the compounds of Formula **(I)** defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the above-mentioned activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

It is to be understood that certain compounds of Formula **(I)** above may exist in unsolvated forms as well as solvated forms, such as, for example, hydrated forms. It is to be understood that the present invention encompasses all such solvated forms that activate TLR7.

It is also to be understood that certain compounds of the Formula **(I)** may exist in crystalline form and exhibit polymorphism. The present invention encompasses all such forms that activate TLR7.

The term “halogen” or “halo” is used herein to denote fluoro, chloro, bromo and iodo.

The term “C₁₋₆alkyl” is intended to mean a saturated carbon chain of 1 to 6 carbon atoms in length which may be straight-chained or branched. However references to individual alkyl groups such as “propyl” are specific for the straight chain version only and references to individual branched-chain alkyl groups such as *tert*-butyl are specific for the branched chain version only. For example, “C₁₋₆alkyl” includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, pentyl, *tert*-pentyl, hexyl and isohexyl. The term “C₁₋₄alkyl” and “C₁₋₇alkyl” are to be construed accordingly.

The term “C₃₋₆cycloalkyl” is intended to mean a saturated 3 to 6 membered monocyclic carbon ring. For example “C₃₋₆cycloalkyl” includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term “C₁₋₆alkoxy” is intended to mean a saturated carbon chain of 1 to 6 carbon atoms in length, which may be straight-chained or branched, linked to oxygen. For example, “C₁₋₆alkoxy” includes, but is not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.

The term “C₁₋₆alkoxyC₁₋₆alkyl” is intended to mean a saturated carbon chain of 1 to 6 carbon atoms in length, which may be straight-chained or branched, linked *via* oxygen to another saturated carbon chain of 1 to 6 carbon atoms in length, which may be straight-chained or branched. For example, “C₁₋₆alkoxyC₁₋₆alkyl” includes, but is not limited to, methoxyethyl, methoxypropyl, ethoxypropyl, propoxyethyl and butoxypropyl. The term “C₁₋₄alkoxyC₂₋₄alkyl” is to be construed accordingly.

The term “hydroxyC₁₋₆alkyl” is intended to mean a saturated carbon chain of 1 to 6 carbon atoms in length, which may be straight-chained or branched, wherein one of the hydrogen atoms has been replaced by a hydroxy group. For example “hydroxyC₁₋₆alkyl” includes, but is not limited to, hydroxymethyl, hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxyisopropyl, 4-hydroxybutyl, hydroxypentyl, hydroxyhexyl and hydroxyisohexyl.

The term “hydroxyC₁₋₆alkoxy” is intended to mean a saturated carbon chain of 1 to 6 carbon atoms in length, which may be straight-chained or branched, linked to oxygen and wherein one of the hydrogen atoms has been replaced by a hydroxy group. For example “hydroxyC₁₋₆alkoxy” includes, but is not limited to, hydroxymethoxy, hydroxyethoxy, 2-hydroxypropoxy, 3-hydroxypropoxy, 1-hydroxyisopropoxy, 4-hydroxybutoxy, hydroxypentoxy and hydroxyhexoxy.

The term “hydroxyC₁₋₆alkoxyC₁₋₆alkyl” is intended to mean a saturated carbon chain of 1 to 6 carbon atoms in length, which may be straight-chained or branched, linked *via* oxygen to another saturated carbon chain of 1 to 6 carbon atoms in length, which may be straight-chained or branched, and wherein one of the hydrogen atoms of one, but not both, of the carbon chains has been replaced by a hydroxy group. For example “hydroxyC₁₋₆alkoxyC₁₋₆alkyl” includes, but is not limited to, hydroxymethoxymethyl, hydroxyethoxymethyl, 2-hydroxypropoxyethyl, 3-hydroxypropoxyethyl, 1-hydroxyisopropoxyethyl, 4-hydroxybutoxypentyl, hydroxypentoxyethyl and hydroxyhexoxyethyl.

The term “aryl” is intended to mean phenyl or naphthyl.

Unless stated otherwise, the term “heterocyclic ring” is intended to mean a 4, 5, 6 or 7 membered fully saturated or partially saturated monocyclic ring which comprises 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulphur linked *via* ring carbon atoms or ring nitrogen atoms. Examples of 4, 5, 6 or 7 membered heterocyclic rings include, but are

not limited to, azetidiny, tetrahydrofuranyl, dihydropyranyl, tetrahydropyranyl, pyrrolinyl, pyrrolidinyl, thiazolidinyl, morpholinyl, oxetanyl, piperidinyl, piperazinyl, dihydropyridinyl, dihydropyrimidinyl, azepanyl and diazepanyl. This definition further comprises sulphur-containing rings wherein the sulphur atom has been oxidised to an S(O) or S(O₂) group.

In further embodiments of the first aspect of the present invention, each of the following definitions of L¹, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², X, and q in paragraphs (1) to (61) hereinafter may be used individually or in combination with one or more of the other following definitions to limit the broadest definition of Formula (I). For example, the skilled person would understand that paragraphs (24), (26), (34), (42) and (58) could be combined to provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R⁴ represents C₁₋₆alkoxy, L¹ represents -O-(CR⁹R¹⁰)_q- and is bonded at the para position of the phenyl ring relative to linkage -X-, q represents 1, 2 or 3 and R⁵ represents NR¹¹R¹² wherein R¹¹ and R¹² both represent methyl. Or, for example, the skilled person would understand that paragraphs (36), (51) and (61) could be combined to provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein L¹ represents -C(O)-O-(CR⁹R¹⁰)_q-, q represents 0 and R⁵ represents methyl.

(1) X represents -CH₂-;

(2) X represents -NR⁸-;

(3) X represents -O-;

(4) X represents -S(O)_n-;

(5) R¹ represents C₁₋₆alkyl, C₂₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy;

(6) R¹ represents C₁₋₆alkyl or hydroxyC₁₋₆alkyl

(7) R¹ represents C₁₋₆alkyl;

(8) R¹ represents butyl;

(9) R² represents hydrogen or C₁₋₆alkyl;

(10) R² represents hydrogen;

(11) R² represents C₁₋₆alkyl;

(12) R² represents phenyl wherein said phenyl is optionally substituted with 1, 2 or 3 substituents selected from R⁶;

- (13) R^2 represents phenyl wherein said phenyl is optionally substituted with 1, 2 or 3 substituents selected from halogen or fluoro C_{1-6} alkyl;
- (14) R^2 represents phenyl wherein said phenyl is optionally substituted with a single substituent selected from $-CH_2-C(O)-O-C_{1-6}$ alkyl;
- 5 (15) R^2 represents phenyl wherein said phenyl is optionally substituted with a single substituent selected from $-CH_2-C(O)-O-CH_3$ or $-CH_2-C(O)-O-CH_2-CH_3$;
- (16) R^3 represents C_{1-6} alkyl;
- (17) R^3 represents methyl;
- (18) R^3 represents C_{1-6} alkoxy;
- 10 (19) R^3 represents $-S-C_{1-6}$ alkyl;
- (20) R^4 is bonded at the ortho position of the phenyl ring relative to linkage $-X-$;
- (21) R^4 represents hydrogen, fluorine, methyl or C_{1-6} alkoxy
- (22) R^4 represents hydrogen or C_{1-6} alkoxy;
- (23) R^4 represents hydrogen;
- 15 (24) R^4 represents C_{1-6} alkoxy;
- (25) R^4 represents methoxy;
- (26) L^1 is bonded at the para position of the phenyl ring relative to linkage $-X-$;
- (27) L^1 is bonded at the meta position of the phenyl ring relative to linkage $-X-$;
- (28) L^1 is bonded at the ortho position of the phenyl ring relative to linkage $-X-$;
- 20 (29) L^1 represents $-(CR^9R^{10})_m-$, $-CH=CH-(CR^9R^{10})_q-$ or $-C\equiv C-(CR^9R^{10})_q-$;
- (30) L^1 represents $-O-(CR^9R^{10})_q-$ or $-C(O)-O-(CR^9R^{10})_q-$;
- (31) L^1 represents $-O-(CH_2)_q-NR^8-(CH_2)_q-$;
- (32) L^1 represents $-O-(CR^9R^{10})_q-$ or $-C(O)-O-(CR^9R^{10})_q-$ wherein q represents 1, 2, 3, 4 or 5 and R^5 represents $-NR^{11}R^{12}$ or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and heterocyclic rings are optionally substituted with 1, 2 or 3 substituents selected from R^7 ;
- 25 (33) L^1 represents $-O-(CR^9R^{10})_q-$ or $-C(O)-O-(CR^9R^{10})_q-$ wherein R^9 and R^{10} both represent hydrogen, q represents 1, 2, 3, 4 or 5 and R^5 represents $-NR^{11}R^{12}$ or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and
- 30

heterocyclic rings are optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

(34) L^1 represents $-O-(CR^9R^{10})_q-$;

(35) L^1 represents $-O-(CR^9R^{10})_q-$ wherein R^9 and R^{10} both represent hydrogen;

5 (36) L^1 represents $-C(O)-O-(CR^9R^{10})_q-$;

(37) L^1 represents a direct bond;

(38) R^5 represents hydroxy, $-NR^{11}R^{12}$, C_{3-6} cycloalkyl, phenyl or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and heterocyclic rings are optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

10 (39) R^5 represents $-NR^{11}R^{12}$, C_{3-6} cycloalkyl, phenyl or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and heterocyclic rings are optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

15 (40) R^5 represents $NR^{11}R^{12}$ or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said heterocyclic ring is optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

(41) R^5 represents $NR^{11}R^{12}$;

20 (42) R^5 represents $NR^{11}R^{12}$ wherein R^{11} and R^{12} both represent methyl;

(43) R^5 represents a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said heterocyclic ring is optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

25 (44) R^5 represents a nitrogen-linked monocyclic 4, 5, 6 or 7 membered heterocyclic ring which optionally comprises, in addition to the nitrogen atom *via* which the heterocyclic ring is linked to L^1 , 1 or 2 further heteroatoms independently selected from O, N or S wherein said heterocyclic ring is optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

30 (45) R^5 represents piperazinyl, piperidinyl or pyrrolidinyl wherein said piperazinyl, piperidinyl or pyrrolidinyl ring is optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

- (46) R^5 represents piperazin-1-yl, piperidin-1-yl or pyrrolidin-1-yl wherein said piperazin-1-yl, piperidin-1-yl or pyrrolidin-1-yl ring is optionally substituted with 1, 2 or 3 substituents selected from R^7 ;
- (47) R^5 represents piperazinyl, piperidinyl or pyrrolidinyl wherein said piperazinyl, piperidinyl or pyrrolidinyl ring is optionally substituted with a single methyl substituent;
- (48) R^5 represents piperazin-1-yl, piperidin-1-yl or pyrrolidin-1-yl wherein said piperazin-1-yl, piperidin-1-yl or pyrrolidin-1-yl ring is optionally substituted with a single methyl substituent;
- (49) R^5 represents an unsubstituted piperazinyl, piperidinyl or pyrrolidinyl ring;
- (50) R^5 represents phenyl;
- (51) R^5 represents methyl;
- (52) R^5 represents hydroxy
- (53) R^8 represents hydrogen or methyl;
- (54) R^8 represents hydrogen;
- (55) R^8 represents methyl;
- (56) q represents 1, 2, 3, 4, 5 or 6;
- (57) q represents 1, 2, 3 or 4;
- (58) q represents 1, 2 or 3;
- (59) q represents 2 or 3;
- (60) q represents 3;
- (61) q represents 0.

Particular novel compounds of Formula (I) include, but are not limited to, the following compounds:

- 5-(4-methoxybenzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine;
 4-(2-amino-4-methyl-6-pentylamino-pyrimidin-5-ylmethyl)-phenol;
 5-(4-(2-(dimethylamino)ethoxy)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine;
 5-(4-(3-(dimethylamino)propoxy)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine;
 6-methyl- N^4 -pentyl-5-(4-(2-(piperidin-1-yl)ethoxy)benzyl)pyrimidine-2,4-diamine;
 6-methyl- N^4 -pentyl-5-(4-(2-(pyrrolidin-1-yl)ethoxy)benzyl)pyrimidine-2,4-diamine;
 5-(4-(2-(benzyl(methyl)amino)ethoxy)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine;
 3-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenoxy)propan-1-ol;

6-methyl-*N*⁴-pentyl-5-(4-(3-(pyrrolidin-1-yl)propoxy)benzyl)pyrimidine-2,4-diamine;
6-methyl-5-(4-(3-(4-methylpiperazin-1-yl)propoxy)benzyl)-*N*⁴-pentylpyrimidine-2,4-diamine;
5 5-(4-(3-(dimethylamino)propoxy)-2-methoxybenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxybenzoate;
(*S*)-methyl 4-((2-amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate;
(*S*)-methyl 4-((2-amino-4-(1-hydroxyheptan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-
10 3-methoxybenzoate;
(*S*)-4-(dimethylamino)butyl 4-((2-amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate benzene sulphonate;
methyl 3-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-4-methoxybenzoate;
methyl 3-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-4-fluorobenzoate;
15 methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-fluorobenzoate;
5-(2-methoxybenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
2-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenol;
5-(2-ethoxybenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
5-(2-(3-(dimethylamino)propoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
20 5-(3-methoxybenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
3-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenol;
5-(3-(3-(dimethylamino)propoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
6-methyl-*N*⁴-pentyl-5-(3-(2-(piperidin-1-yl)ethoxy)benzyl)pyrimidine-2,4-diamine;
5-(3-(2-(dimethylamino)ethoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
25 6-methyl-*N*⁴-pentyl-5-(3-(2-(pyrrolidin-1-yl)ethoxy)benzyl)pyrimidine-2,4-diamine;
5-(3-((dimethylamino)methyl)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
5-(4-(3-(dimethylamino)prop-1-ynyl)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
5-(4-(3-(dimethylamino)propyl)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
5-(3-(3-(dimethylamino)propyl)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;
30 5-(4-(3-(dimethylamino)propoxy)-2-methylbenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;

(*R*)-methyl 2-(3-(1-(2-amino-5-(4-(3-(dimethylamino)propoxy)benzyl)-6-methylpyrimidin-4-ylamino)-3-hydroxypropyl)phenyl)acetate;

(*R*)-methyl 2-(3-(1-(2-amino-5-(4-(3-(dimethylamino)propoxy)-2-methoxybenzyl)-6-methylpyrimidin-4-ylamino)-3-hydroxypropyl)phenyl)acetate;

5 and pharmaceutically acceptable salts thereof.

In one embodiment there is provided (*S*)-4-(dimethylamino)butyl 4-((2-amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate.

In a further embodiment there are provided compounds of Formula (I) selected from:

10 3-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxyphenoxy)propan-1-ol;

5-(2-methoxy-4-(3-morpholinopropoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;

15 5-(2-methoxy-4-(3-(4-methylpiperazin-1-yl)propoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine;

5-(4-(4-(dimethylamino)butyl)-2-methoxybenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine; and

(*S*)-2-(2-amino-5-(4-(hydroxymethyl)-2-methoxybenzyl)-6-methylpyrimidin-4-ylamino)pentan-1-ol;

20 and pharmaceutically acceptable salts thereof.

In one embodiment of the invention there is provided any Example described herein, or a pharmaceutically acceptable salt thereof.

A suitable pharmaceutically-acceptable salt of a compound of the Formula (I) is, for example, an acid-addition salt of a compound of the Formula (I), for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic,
25 sulphuric, trifluoroacetic, citric or maleic acid.

The compounds of the invention may be administered in the form of a pro-drug, that is a compound that is broken down in the human or animal body to release a compound of the invention. A pro-drug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the invention. A pro-drug can be formed
30 when the compound of the invention contains a suitable group or substituent to which a property-modifying group can be attached. Examples of pro-drugs include *in-vivo*

cleavable amide derivatives that may be formed at an amino group in a compound of the Formula (I).

Accordingly, the present invention includes those compounds of the Formula (I) as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the Formula (I) that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the Formula (I) may be a synthetically-produced compound or a metabolically-produced compound.

A suitable pharmaceutically-acceptable pro-drug of a compound of the Formula (I) is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.

Various forms of pro-drug have been described, for example in the following documents :-

- a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985);
- c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Pro-drugs", by H. Bundgaard p. 113-191 (1991);
- d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
- e) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77, 285 (1988);
- f) N. Kakeya, *et al.*, Chem. Pharm. Bull., 32, 692 (1984);
- g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", A.C.S. Symposium Series, Volume 14; and
- h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.


A suitable pharmaceutically-acceptable pro-drug of a compound of the Formula (I) that possesses an amino group is, for example, an *in-vivo* cleavable amide derivative thereof. Suitable pharmaceutically-acceptable amides from an amino group include, for example an amide formed with C₁₋₁₀alkanoyl groups such as an acetyl, benzoyl,

phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, *N*-alkylaminomethyl, *N,N*-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C₁₋₄alkyl)piperazin-1-ylmethyl.


The *in-vivo* effects of a compound of the Formula **(I)** may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the Formula **(I)**. As stated hereinbefore, the *in-vivo* effects of a compound of the Formula **(I)** may also be exerted by way of metabolism of a precursor compound (a pro-drug).

Preparation of Compounds of Formula (I)



Certain processes for the synthesis of compounds of Formula **(I)** are provided as a further feature of the invention. Thus, according to a further aspect of the invention there is provided a process for the preparation of a compound of Formula **(I)** or a pharmaceutically acceptable salt thereof, which comprises a process **(a)**, **(b)**, **(c)** or **(d)** wherein, unless otherwise defined, the variables are as defined hereinbefore for compounds of Formula **(I)**:
(a) when R³ represents C₁₋₆alkyl and L¹ represents -O-(CR⁹R¹⁰)_q-, reaction of a compound of Formula **(IX)** with a group halo-(CR⁹R¹⁰)_q-R⁵;



(b) when L¹ represents -C(O)-O-(CR⁹R¹⁰)_q- and R⁵ represents NR¹¹R¹², reaction of an acid of Formula **(XVI)** with an alcohol of formula OH-(CR⁹R¹⁰)_q-NR¹¹R¹² in the presence of oxalyl chloride or thionyl chloride, a suitable coupling agent and optionally a suitable base;




(c) when L^1 represents $-(CR^9R^{10})_m-$ (and m represents 2, 3, 4, 5 or 6), $-\text{CH}=\text{CH}-(CR^9R^{10})_q-$ or $-\text{C}\equiv\text{C}-(CR^9R^{10})_q-$, reaction of a compound of Formula **(XVII)** with a compound of Formula **(XVIII)** in the presence of copper iodide, a suitable catalyst and a suitable base;



5

(d) when R^3 represents C_{1-6} alkoxy or $-S-C_{1-6}$ alkyl, reaction of a compound of Formula **(XXXIII)** with the appropriate alcohol or alkylthiol in the presence of a suitable base;




and thereafter, if necessary:

- 10 (i) converting a compound of Formula **(I)** into another compound of Formula **(I)**;
- (ii) removing any protecting groups;
- (iii) separating a racemic mixture into separate enantiomers;
- (iv) preparing a pharmaceutically acceptable salt thereof; and/or

(v) preparing a crystalline form thereof.

Compounds of Formula **(Ia)** in which X represents CH₂, R³ represents C₁₋₆alkyl, L¹ represents -O-(CR⁹R¹⁰)_q-, Et represents an ethyl group, R⁴ is other than C₁₋₆alkoxy and all other variables are as defined hereinbefore for compounds of Formula **(I)**, may be prepared as described in the following reaction Scheme 1.



Scheme 1

Step (i) - A compound of Formula **(IV)** can be prepared by reaction of a compound of Formula **(III)** with a compound of Formula **(II)**. The reaction may be carried out in the

presence of acetic acid and piperidine in a suitable solvent, such as toluene, and at a suitable temperature, for example 50°C to 150°C.

Step (ii) - Compounds of Formula **(V)** can be prepared by reduction of a compound of Formula **(IV)**. The reaction may be carried out with a catalyst such as Pd/C under a H₂ atmosphere (1-20 bar) in a suitable solvent, such as EtOH, and at a suitable temperature, for example 20°C to 100°C.

Step (iii) - Compounds of Formula **(VI)** may be prepared by reacting a compound of Formula **(V)** with guanidine or guanidine carbonate in a suitable solvent, such as MeOH or EtOH, and at a suitable temperature, for example 50°C to 150°C.

Step (iv) - Compounds of Formula **(VII)** may be prepared by reacting a compound of Formula **(VI)** with phosphorous oxychloride, at a suitable temperature, for example 50°C to 110°C.


Step (v) - Compounds of Formula **(VIII)** may be prepared by reacting a compound of Formula **(VII)** with an excess of amine of formula NH₂CHR¹R² in a suitable solvent, such as butanol or 1,4-dioxane, at a suitable temperature, for example 50°C to 150°C. Alternatively, the reaction may be performed in a microwave at a suitable temperature, for example 50°C to 200°C.

Step (vi) - Compounds of Formula **(IX)** may be prepared by reacting a compound of Formula **(VIII)** with a solution of BBr₃ in a suitable solvent, such as DCM, and at a suitable temperature, for example 0°C to 15°C.

Step (vii) - compounds of Formula **(IX)** may be reacted with a group halo-R⁵ or halo-(CR⁹R¹⁰)_q-R⁵ in the presence of a suitable base, for example Cs₂CO₃, in a suitable solvent, for example NMP or DMF, optionally in the presence of NaI and at a suitable temperature, for example 50°C to 150°C, to provide a compound of Formula **(Ia)**.


Alternatively, compounds of Formula **(VIII)** may be prepared by reacting a compound of Formula **(X)**, in which R¹³ represents an aryl group, with excess of amine of formula NH₂CHR¹R². The reaction may be carried out in a suitable solvent, such as butanol or 1,4-dioxane, and at a suitable temperature, for example 50°C to 150°C.

Alternatively, the reaction may be performed in a microwave at a suitable temperature, for example 50°C to 200°C.



A compound of Formula (X) may be prepared by reacting a compound of Formula (VI) with an aryl sulphonylchloride of formula $R^{13}SO_2Cl$. The reaction may be carried out in a suitable solvent, such as DCM, in the presence of a suitable base, such as triethylamine or DIPEA, and with the addition of a catalyst, such as DMAP, at a suitable temperature, for example $0^\circ C$ to $50^\circ C$.


Alternatively compounds of Formula (V) may be prepared as shown in Scheme 2 by reacting a compound of Formula (III) with a base, such as NaH, in a suitable solvent, such as THF or DMF, at a suitable temperature, for example $0^\circ C$ to r.t. ($20^\circ C$), followed by addition of a compound of Formula (XI) wherein LG represents a suitable leaving group, for example bromine or chlorine. The reaction is then preferably heated, for example at $50^\circ C$ to $100^\circ C$, optionally in the presence of an additive such as KI.



Scheme 2


Alternatively compounds of Formula (V) may be prepared by a Heck reaction between a compound of Formula (XII) and a compound of Formula (XIII) as shown in Scheme 3 wherein Hal represents bromine or iodine. The reaction may be carried out using a palladium catalyst, such as $Pd(OAc)_2$ or 1,1'-bis(di-*tert*-butylphosphino)ferrocene-palladium(II) chloride ($Pd-118$), a base such as $NaHCO_3$ or dicyclohexylmethylamine, and

tetrabutylammonium chloride or bromide. The reaction is performed in a suitable solvent, such as THF or DMA, and at a suitable temperature, for example 50°C to 150°C.




Scheme 3

Alternatively compounds of Formula (I) wherein X represents CH₂, and L¹ represents -C(O)-O- and R⁵ represents methyl can be prepared according to Scheme 2 from compounds of Formula (XIV) where LG represents bromo and which are either commercially available or prepared by bromination of the appropriate precursor using *N*-bromosuccinimide in the presence of light and a radical initiator such as di-benzoyl peroxide or 2,2'-azobisisobutyronitrile in a suitable solvent, such as DCM, CHCl₃ or CCl₄.




Compounds of Formula (Ib) wherein L¹ represents -C(O)-O-(CR⁹R¹⁰)_q- and R⁵ represents NR¹¹R¹² may be prepared according to Scheme 4 from compounds of type (XV) by hydrolysis of the ester in the presence of a base, such as aqueous LiOH containing an alcohol such as EtOH, and at a suitable temperature, for example 20°C to 50°C, followed by activation of the acid of Formula (XVI), for example with COCl₂ or SOCl₂ or with a coupling agent such as *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate or benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate, and reaction with a suitable alcohol group containing NR¹¹R¹² in an organic solvent such as NMP, DMF, MeCN or THF and usually in the presence of a suitable base, for example triethylamine or DIPEA, and at a suitable temperature, for example 0°C to 50°C.




Scheme 4

Compounds of Formula (Ic), (Id) or (Ie) wherein L¹ represents $-(CR^9R^{10})_m-$ (and m represents 2, 3, 4, 5 or 6), $-\text{CH}=\text{CH}-(CR^9R^{10})_q-$ or $-\text{C}\equiv\text{C}-(CR^9R^{10})_q-$ may be prepared according to Scheme 5 from compounds of Formula (XVII) by reaction with alkynes of Formula (XVIII) in the presence of CuI followed by addition of compounds of Formula (XVII) and a Pd(0) catalyst, such as Pd(PPh₃)₄, in a suitable solvent, such as THF, in the presence of a suitable base, such as triethylamine or DIPEA, and at a suitable temperature, e.g. 50°C-100°C for 6-24 hours, to give compounds of Formula (Ic). Reduction of compounds of Formula (Ic) with a catalyst, such as Pd/C, in a suitable solvent, such as EtOH under a pressure of H₂, e.g. 1-3 bar, provides compounds of Formula (Id). Further reduction under the same conditions provides compounds of Formula (Ie).




Scheme 5


Compounds of Formula **(I)** where L^1 represents a direct bond and R^5 represents a monocyclic 4, 5, 6 or 7 membered heterocyclic ring may be prepared according to Scheme 3 from compounds of Formula **(XIX)** and compounds of Formula **(XX)** and following the steps in reaction Scheme 1 from compounds of Formula **(V)**. The reaction may be carried out using a palladium catalyst, such as palladium acetate or Pd-118, a base such as $NaHCO_3$ or dicyclohexylmethylamine, and tetrabutylammonium chloride or bromide. The reaction is performed in a suitable solvent such as THF or DMA and at a suitable temperature, for example $50^\circ C$ to $150^\circ C$




A compound of Formula **(I)** in which X represents a sulphur atom may be prepared by reacting a compound of Formula **(XXI)** with a compound of Formula **(XXII)** and then by following the steps in reaction Scheme 1 from Formula **(VI)**. The reaction may be carried out in a suitable solvent, such as ethylene glycol, and a base such as K_2CO_3 , and at a suitable temperature, for example $80^\circ C$ to $200^\circ C$.




A compound of Formula **(I)** in which X represents an oxygen atom may be prepared by reacting a compound of Formula **(XXIII)**, where LG represents a suitable leaving group, for example bromine, with a compound of Formula **(XXIV)** and then by following the steps in reaction Scheme 1 from Formula **(V)**. The reaction may be carried out in a suitable solvent, such as THF, and in the presence of a base, such as K_2CO_3 , and at a suitable temperature, for example $20^\circ C$ to $100^\circ C$.




A compound of Formula (I) in which X represents a group NH may be prepared by reacting a compound of Formula (XXV) with a compound of Formula (XXVI) then by following the steps in reaction Scheme 1 from Formula (V). The benzyl protecting group may be removed by catalytic hydrogenation at a convenient step in the route. The reaction may be carried out in a suitable solvent, such as toluene, and with a suitable catalyst, such as rhodium acetate, and at a suitable temperature, for example 50°C to 150°C.



A compound of Formula (I) in which X represents a group NR⁸, wherein R⁸ is C₁₋₆alkyl, may be prepared by reacting a compound of Formula (XXV) with a compound of Formula (XXVII) then by following the steps in reaction Scheme 1 from Formula (V).



A compound of Formula (I) in which R³ represents a group C₁₋₆alkoxy or -S-C₁₋₆alkyl may be prepared according to Scheme 6.



Scheme 6

Step (i) - Compounds of Formula (XXIX) may be prepared by reacting a compound of Formula (XXVIII) with guanidine or guanidine carbonate in a suitable solvent, such as MeOH or EtOH, and at a suitable temperature, for example 50°C-150°C.

Step (ii) - Compounds of Formula (XXX) may be prepared by reacting a compound
5 of Formula (XXIX) with POCl₃, at a suitable temperature, for example 50°C to 110°C.

Step (iii) - Compounds of Formula (XXXI) may be prepared by reacting a compound of Formula (XXX) with excess of an amine of Formula NH₂CHR¹R², in a suitable solvent, such as butanol or 1,4-dioxane, and at a suitable temperature, for example 50°C to 150°C. Alternatively, the reaction can be performed in a microwave at a suitable
10 temperature, for example 0°C to 200°C.

Step (iv) - A compound of Formula (I) may be prepared by reacting a compound of Formula (XXXI) with the appropriate alcohol or alkylthiol in the presence of a suitable base, such as NaH.

Biological Assays

15 The ability of compounds to activate TLR7 *in vitro* was assessed using the human TLR7 assay described below.

Human TLR7 assay

Recombinant human TLR7 was stably expressed in a HEK293 cell line already stably expressing the pNiFty2-SEAP reporter plasmid; integration of the reporter gene was
20 maintained by selection with the antibiotic zeocin. The most common variant sequence of human TLR7 (represented by the EMBL sequence AF240467) was cloned into the mammalian cell expression vector pUNO and transfected into this reporter cell-line. Transfectants with stable expression were selected using the antibiotic blasticidin. In this reporter cell-line, expression of secreted alkaline phosphatase (SEAP) is controlled by an
25 NFkB/ELAM-1 composite promoter comprising five NFkB sites combined with the proximal ELAM-1 promoter. TLR signaling leads to the translocation of NFkB and activation of the promoter results in expression of the SEAP gene. TLR7-specific activation was assessed by determining the level of SEAP produced following overnight incubation of the cells at 37°C with the standard compound in the presence of 0.1% (v/v)
30 dimethylsulfoxide (DMSO). Concentration dependent induction of SEAP production by compounds was expressed as the concentration of compound which produced half of the maximal level of SEAP induction for that compound (EC₅₀). TLR7 activity for compounds

of the present invention was assessed using the human TLR7 assay and the results are shown in Table 1 below wherein the degree of TLR7 activation for each compound is expressed as a pEC₅₀ value.

Table 1

Ex. No.	pEC50	Ex. No.	pEC50	Ex. No.	pEC50
1	5.7	15	6.9	29	6.5
2	5.9	16	7.3	30	7
3	7.2	17	5.5	31	7
4	7.2	18	5.7	32	6.6
5	6.9	19	7.2	33	6.6
6	7	20	6.9	34	5.7
7	6.2	21	6.5	35	6.5
8	6.3	22	5.9	36	7.3
9	7.2	23	5.6	37	8.1
10	7.1	24	5.3	38	8.2
11	8.6	25	6.1	39	8.4
12	7.2	26	6.2	40	7.7
13	7	27	6.4		
14	8	28	5.9		

5

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier. The pharmaceutical composition may be used in the treatment of cancer. The composition may be in a form suitable for oral administration, for example as a tablet or capsule; for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion; for topical administration as an ointment or cream; or for rectal administration as a suppository.

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, could also be administered as an air spray for inhalation. The air spray (e.g., spray, aerosol, dry powder preparation, etc.) could be optionally formulated as an aqueous solution or suspension, or as an aerosol delivered from a pressurized pack such as a pressurised metered dose inhaler by using, for example, a liquefied propellant. A dry powder preparation may also be used. An aerosol appropriate for inhalation may be either a suspension or solution, and would typically contain the compound of Formula (I), or a

pharmaceutically acceptable salt thereof, and any appropriate propellants such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or a mixture thereof. Specifically, it may contain hydrofluoroalkane, particularly 1,1,1,2-tetrafluoroethane, heptafluoroalkane (HFA) such as 1,1,1,2,3,3,3-heptafluoro-n-propane, or a mixture thereof. An aerosol may optionally contain an additional preparation excipient well-known to those skilled in the art such as surfactant (e.g., oleic acid or lecithin) and cosolvent (e.g., ethanol), etc. Specifically, an aerosol preparation could be delivered using the inhaler known as “TurbuhalerTM”.

For oral administration the compound of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide. Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.

For the preparation of soft gelatine capsules, the compound of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets. Also liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.

Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.

The compound of Formula **(I)** will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg/m² body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of

active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

As used herein, the term "treatment" is intended to have its normal everyday meaning of dealing with a disease in order to entirely or partially relieve one, some or all of its symptoms, or to correct or compensate for the underlying pathology.

As used herein, the term "prophylaxis" is intended to have its normal everyday meaning and includes primary prophylaxis to prevent the development of the disease and secondary prophylaxis whereby the disease has already developed and the patient is temporarily or permanently protected against exacerbation or worsening of the disease or the development of new symptoms associated with the disease.

The compounds defined in the present invention are effective activators of TLR7 *in vitro*. Accordingly, the compounds of the present invention are expected to be potentially useful agents in the treatment of diseases or medical conditions mediated alone or in part by TLR7. For example, the following diseases and conditions listed in paragraphs 1 to 8 below may be treatable with compounds of the present invention.

1. respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and

chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and
5 iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus;

2. skin: psoriasis, atopic dermatitis, contact dermatitis or other eczematous
10 dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-
15 Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions;

3. eyes: blepharitis; conjunctivitis, including perennial and vernal allergic
conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune, degenerative
20 or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial;

4. genitourinary: nephritis including interstitial and glomerulonephritis; nephrotic
syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer;
acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-
25 vaginitis; Peyronie's disease; erectile dysfunction (both male and female);

5. allograft rejection: acute and chronic following, for example, transplantation of
kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or
chronic graft versus host disease;

6. other auto-immune and allergic disorders including rheumatoid arthritis, irritable
30 bowel syndrome, systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic

thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, antiphospholipid syndrome and Sazary syndrome;

7. oncology: treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,

8. infectious diseases: virus diseases such as genital warts, common warts, plantar warts, hepatitis B, hepatitis C, herpes simplex virus, molluscum contagiosum, variola, human immunodeficiency virus (HIV), human papilloma virus (HPV), cytomegalovirus (CMV), varicella zoster virus (VZV), rhinovirus, adenovirus, coronavirus, influenza, para-influenza; bacterial diseases such as tuberculosis and mycobacterium avium, leprosy; other infectious diseases, such as fungal diseases, chlamydia, candida, aspergillus, cryptococcal meningitis, pneumocystis carinii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection and leishmaniasis.

It is envisaged that for the methods of treatment mentioned herein, the compound of Formula (I) will be administered to a mammal, more particularly a human being. Similarly, for the uses of a compound of Formula (I) for the treatment of diseases or medical conditions mentioned herein, it is envisaged that the compound of Formula (I) will be administered to a mammal, more particularly a human being.

According to a another aspect of the invention, there is therefore provided a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for use as a medicament.

According to a further aspect of the invention, there is provided a compound of Formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt thereof for use in the treatment of a disease mediated through TLR7. In one embodiment of the invention, said disease mediated through TLR7 is cancer. In a further embodiment of the invention, said cancer is selected from prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors. In one embodiment of the invention, said disease mediated through TLR7 is asthma, COPD,

allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

According to a further aspect of the invention, there is provided the use of a compound of Formula **(I)** as defined hereinbefore, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of a disease mediated through TLR7. In one embodiment of the invention, said disease mediated through TLR7 is cancer. In a further embodiment of the invention, said cancer is selected from prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors. In one embodiment of the invention, said disease mediated through TLR7 is asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

According to a further aspect of the invention, there is provided the use of a compound of Formula **(I)** as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of cancer. In one embodiment of the invention, said cancer is selected from prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors.

According to a further aspect of the invention, there is provided the use of a compound of Formula **(I)** as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

In one aspect of the invention there is provided the a compound of Formula **(I)** or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.

According to a further aspect of the invention, there is provided a method of using a compound of Formula **(I)** as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for the treatment of cancer. In one embodiment of the invention, said cancer is selected from prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors.

According to a further aspect of the invention, there is provided a method of using a compound of Formula **(I)** as defined hereinbefore, or a pharmaceutically acceptable salt thereof, for the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

5 According to a further aspect of the invention, there is provided a method of treating a human suffering from a disease in which activation of TLR7 is beneficial, comprising the steps of administering to a person in need thereof of a therapeutically effective amount of a compound of Formula **(I)** as defined hereinbefore, or a pharmaceutically acceptable salt thereof. In one embodiment of the invention, the disease
10 in which activation of TLR7 is beneficial is cancer. In a further embodiment of the invention, said cancer is selected from prostate cancer, breast cancer, lung cancer, uterus cancer, pancreatic cancer, liver cancer, renal cancer, ovarian cancer, colon cancer, stomach cancer, skin cancer, cerebral tumor, malignant myeloma and lymphoproliferative tumors. In one embodiment of the invention, the disease in which activation of TLR7 is beneficial
15 is asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.

In any aspect or embodiment described herein the cancer may be prostate cancer.

In any aspect or embodiment described herein the cancer may be breast cancer.

In any aspect or embodiment described herein the cancer may be lung cancer.

20 In any aspect or embodiment described herein the cancer may be uterus cancer.

In any aspect or embodiment described herein the cancer may be pancreatic cancer.

In any aspect or embodiment described herein the cancer may be liver cancer.

In any aspect or embodiment described herein the cancer may be renal cancer.

In any aspect or embodiment described herein the cancer may be ovarian cancer.

25 In any aspect or embodiment described herein the cancer may be colon cancer.

In any aspect or embodiment described herein the cancer may be stomach cancer.

In any aspect or embodiment described herein the cancer may be skin cancer.

In any aspect or embodiment described herein the cancer may be cerebral tumor.

30 In any aspect or embodiment described herein the cancer may be malignant myeloma cancer.

In any aspect or embodiment described herein the cancer may be lymphoproliferative tumors.

The anti-cancer treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:-

- 5 (i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, 10 cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinese inhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like 15 etoposide and teniposide, amsacrine, topotecan and camptothecin);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and idoxifyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example 20 megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;
- (iii) anti-invasion agents [for example c-Src kinase family inhibitors like 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530; International Patent Application WO 01/94341), N-(2- 25 chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; *J. Med. Chem.*, 2004, 47, 6658-6661) and bosutinib (SKI-606), and metalloproteinase inhibitors like marimastat, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase];
- (iv) inhibitors of growth factor function: for example such inhibitors include growth 30 factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbix, C225] and any growth factor or growth factor receptor

antibodies disclosed by Stern et al. Critical reviews in oncology/haematology, 2005, Vol. 54, pp11-29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as

- 5 *N*-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839), *N*-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-*N*-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin
- 10 growth factor family; inhibitors of the platelet-derived growth factor family such as imatinib and/or nilotinib (AMN107); inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006), tipifarnib (R115777) and lonafarnib (SCH66336)), inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3
- 15 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; aurora kinase inhibitors (for example AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 AND AX39459) and cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors;
- (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial
- 20 growth factor, [for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and for example, a VEGF receptor tyrosine kinase inhibitor such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), pazopanib (GW 786034) and 4-(4-fluoro-2-methylindol-5-ylloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212),
- 25 compounds such as those disclosed in International Patent Applications WO97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin)];
- (vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669,
- 30 WO 01/92224, WO 02/04434 and WO 02/08213;
- (vii) an endothelin receptor antagonist, for example zibotentan (ZD4054) or atrasentan;

(viii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;

(ix) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

(x) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies, approaches to decrease the function of immune suppressive cells such as regulatory T cells, myeloid-derived suppressor cells or IDO (indoleamine 2,3,-deoxygenase)-expressing dendritic cells, and approaches using cancer vaccines consisting of proteins or peptides derived from tumour-associated antigens such as NY-ESO-1, MAGE-3, WT1 or Her2/neu.

According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula **(I)** as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.

According to this aspect of the invention there is provided a combination suitable for use in the treatment of cancer comprising a compound of Formula **(I)** as defined hereinbefore, or a pharmaceutically acceptable salt thereof, and any one of the anti tumour agents listed under (i) – (ix) above.

Therefore in a further aspect of the invention there is provided a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) – (ix) herein above.

Herein, where the term “combination” is used it is to be understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention “combination” refers to simultaneous administration. In another aspect of the invention “combination” refers to separate administration. In a further aspect of the invention “combination” refers to sequential administration. Where the administration is sequential

or separate, the delay in administering the second component should not be such as to lose the beneficial effect of the combination.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) – (ix) herein above, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) – (ix) herein above, in association with a pharmaceutically acceptable diluent or carrier for use in the treatment of cancer.

According to another feature of the invention there is provided the use of a compound of the Formula **(I)**, or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) – (ix) herein above, in the manufacture of a medicament for use in cancer in a warm-blooded animal, such as man.

According to another feature of the invention there is provided a compound of the Formula **(I)**, or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) – (ix) herein above for use in the treatment of cancer in a warm-blooded animal, such as man.

Therefore in an additional feature of the invention, there is provided a method of treating cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) – (ix) herein above.

According to a further aspect of the present invention there is provided a kit comprising a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent selected from one listed under (i) – (ix) herein above.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, in a first unit dosage form;
- b) an anti-tumour agent selected from one listed under (i) – (ix) herein above; in a second unit dosage form; and
- 5 c) container means for containing said first and second dosage forms.

In one aspect of the invention the compounds of Formula **(I)** may be useful as vaccine adjuvants.

As a further aspect of the invention there is provided a compound of formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined herein, for use as a vaccine adjuvant.

10 As a further aspect of the invention there is provided the use of a compound of formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined herein, as a vaccine adjuvant, in the manufacture of a vaccine for the treatment of a disease or condition.

The invention still further provides a method of treating, or reducing the risk of, a disease or condition, which method comprises administering to a patient in need thereof a
15 therapeutically effective amount of a vaccine and a compound of formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined herein.

The invention still further provides a method of increasing the response to a vaccine in a patient, which method comprises administering to a patient in need thereof a therapeutically effective amount of a vaccine and a compound of formula **(I)**, or a
20 pharmaceutically acceptable salt thereof, as defined herein.

Examples

The invention will now be illustrated with the following Examples in which generally, unless stated otherwise, all starting materials are commercially available. All
25 solvents and commercial reagents used in the Examples were of laboratory grade and were used as received. All operations were carried out at ambient temperature, *i.e.* in the range 17 to 28°C, typically 20°C, and where appropriate, under an atmosphere of an inert gas such as nitrogen. ‘Microwave’ heating refers to heating to constant temperature, using variable power microwave irradiation in a CEM DiscoverTM microwave reactor.

30 Hydrogenation reactions were carried out using a Büchi PetericTM system or a ThalesNano H-CubeTM system, as detailed. Concentration of all solutions was carried out by

evaporation under reduced pressure (*in vacuo*), *e.g.* using a Büchi RotavaporTM rotary evaporator.

Thin Layer Chromatography (TLC) was carried out using aluminium- or glass-backed plates coated with silica (particle size <63 µm; porosity 60 Å; surface area ~500 m²/g), with a fluorescent (UV₂₅₄) indicator. Following elution, the plates were visualized by either UV₂₅₄ irradiation, or developed with a suitable indicator, such as iodine (pre-absorbed onto silica), an aqueous solution of potassium permanganate, or an aqueous solution of cerium (IV) ammonium nitrate. Examples of indicator preparations can be found in 'Experimental Organic Chemistry: Preparative and Microscale' 2nd Ed. (Harwood, L., Moody, C. and Percy, J.), WileyBlackwell, 1998.

Analytical HPLC was carried out using either a Waters XBridgeTM C8 3.5 µm column eluting with a gradient of MeCN in either 0.1% aqueous trifluoroacetic acid, 0.1% aqueous formic acid, 0.1% aqueous ammonium acetate or 0.1% aqueous NH₃; a Waters XBridgeTM C18 3.5 µm column with a gradient of MeCN in 0.1% aqueous NH₃; a Waters SymmetryTM C18 3.5 µm column with a gradient of MeCN in 0.1% aqueous trifluoroacetic acid; a Waters SunfireTM C8 3.5 µm column with a gradient of MeCN in 0.1% aqueous trifluoroacetic acid; or a Phenomenex GeminiTM C18 3 µm column with a gradient of MeCN in 0.1% aqueous trifluoroacetic acid. UV spectra of the eluted peaks were measured using a diode array on an Agilent 1100TM system, or equivalent.

Medium pressure liquid chromatography (MPLC) on silica (particle size <63 µm; porosity 60 Å; surface area ~500 m²/g) was carried out using pre-packed Biotage FLASHTM columns or equivalent, *e.g.* Thomson SINGLE StEPTM, Biotage IsoluteTM, Teledyne Isco RediSepTM, or Silicycle UltraPure silica columns at recommended solvent flow rates and sample loadings. Fraction purity was determined by either TLC or analytical HPLC.

Preparative HPLC was carried out using either a Phenomenex GeminiTM C18 5 µm column, a Waters SunfireTM C18 5 µm column, a Waters XBridgeTM C8 5 µm column or a Waters XTerraTM 5 µm, unless otherwise detailed, using either MeCN in aqueous 0.1-0.2% trifluoroacetic acid, MeCN in aqueous 0.1-0.2% ammonium acetate, or MeCN in an aqueous 0.1-0.2% NH₃ solution as eluent, as detailed. Fractions were collected following detection by UV spectroscopy at a wavelength such as 220 or 254 nm. Fraction purity was determined by either TLC or analytical HPLC.

Proton nuclear magnetic resonance (^1H NMR) spectra were recorded on Bruker Avance 600 (600 MHz), a Bruker DRX 500 (500 MHz) or a Varian UnityInova 500 MHz, 400 MHz or 300 MHz instrument. Either the central peaks of chloroform-*d* (CDCl_3 ; δ_{H} 7.27 ppm), dimethylsulfoxide-*d*₆ (d_6 -DMSO; δ_{H} 2.50 ppm) or an internal standard of tetramethylsilane (TMS; δ_{H} 0.00 ppm) were used as references. Unless otherwise specified, ^1H NMR spectra were determined using deuterated DMSO. The following abbreviations are used for NMR data: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, tt = triplet of triplets, br = broad, quintet = qn. Mass spectra were recorded on an Agilent MSD or similar equipment (+ve and -ve APCI and/or electrospray (unless otherwise stated: in "multimode +")) following analytical HPLC.

All other processes were carried out using standard laboratory techniques, *e.g.* as detailed in 'Experimental Organic Chemistry: Preparative and Microscale' 2nd Ed. (Harwood, L., Moody, C. and Percy, J.), WileyBlackwell, 1998.

The following abbreviations may be used in the scientific parts of this specification:

EtOAc = ethyl acetate; DCM = dichloromethane; NMP = *N*-methylpyrrolidinone; DMF = *N,N*-dimethylformamide; DMSO = dimethylsulfoxide; THF = tetrahydrofuran; MeOH = methanol; EtOH = ethanol; MeCN = acetonitrile; Pd/C = palladium on carbon; DMAP = 4-dimethylaminopyridine; sat. = saturated; aq. = aqueous; DMA = *N,N*-dimethylacetamide; conc. = concentrated; r.t. = room temperature; h = hours; min(s) = mins.; M = molar; MS = mass spectrometry; APCI = atmospheric chemical ionisation method; ESI = electron spray ionisation method; SCX = Solid phase extraction with a sulfonic acid sorbent; HPLC = High performance liquid chromatography; RPHPLC = Reverse-phase high performance liquid chromatography; FCC = flash column chromatography using silica; DIPEA = diisopropylethylamine.

Example 1: 5-(4-Methoxybenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine

(i) 2-(4-Methoxy-benzyl)-3-oxo-butyric acid ethyl ester

Ethyl acetoacetate (11.7 mL) was added to a solution of 4-methoxy-benzaldehyde (10.0 g) in toluene (150 mL). Piperidine (0.80 mL) and acetic acid (2.30 mL) were then added and the mixture was heated at reflux for 20 h. The solvent was then removed and the resulting orange oil was dissolved in EtOH (0.30 L) and 10% Pd/C (0.50 g) was added and stirred under H_2 (2 bar) for 3 h. The reaction mixture was filtered through diatomaceous earth (CeliteTM) and the solvent removed by evaporation. The crude product was purified by

FCC to give the subtitle compound as an oil (12.7 g); ^1H NMR: 7.19 (1H, t), 6.75 (3H, m), 4.15 (2H, q), 3.78 (4H, m), 3.13 (2H, d), 2.20 (3H, s), 1.26 (3H, t); LC-MS m/z 249 ESI.

(ii) 2-Amino-5-(4-methoxy-benzyl)-6-methyl-pyrimidin-4-ol

Guanidium carbonate (3.90 g) was added to a solution of the product from step (I) (5.30 g) in ethanol (50.0 mL) and heated at 80°C for 15 h. After cooling the product was filtered off as a solid, this was suspended in water and collected by filtration, washed with EtOAc and dried to give the subtitle compound (3.40 g); ^1H NMR: 10.83 (1H, s), 7.08 (2H, d), 6.79 (2H, d), 6.34 (2H, s), 3.69 (3H, s), 3.56 (2H, s), 2.00 (3H, s); LC-MS m/z 246 ESI.

(iii) 4-Chloro-5-(4-methoxy-benzyl)-6-methyl-pyrimidin-2-ylamine

The product of step (ii) (1.00 g) was added to POCl_3 (10.0 mL) and the mixture was heated at 100°C for 15 h. The solvent was removed and the residue diluted with water and adjusted to pH 7 with sat NaHCO_3 . This mixture was heated at 50°C for 2 h, then extracted with EtOAc, dried and solvent removed to give the subtitle compound as a white solid (0.71 g); ^1H NMR: 7.02 (2H, d), 6.85 (2H, d), 6.84 (2H, s), 3.88 (2H, s), 3.71 (3H, s), 2.21 (3H, s); LC-MS m/z 263 ESI.

(iv) 5-(4-Methoxy-benzyl)-6-methyl- N^4 -pentyl-pyrimidine-2,4-diamine

To the product of step (iii) (3.00 g) in dioxane (30.0 mL), pentylamine (5.30 mL) was added and the mixture was heated at 100°C for 48 h. The solvent was removed and the residue was dissolved in EtOAc and washed with sat. NaHCO_3 , dried and solvent removed.

The crude compound was purified by FCC to give the title compound as a white solid (2.30 g); ^1H NMR: 7.02 (2H, d), 6.81 (2H, d), 6.31-6.22 (1H, m), 5.83 (2H, s), 3.69 (3H, s), 3.66 (2H, s), 3.25 (2H, q), 2.03 (3H, s), 1.43 (2H, q), 1.28-1.06 (4H, m), 0.81 (3H, t); LC-MS m/z 315.

Example 2: 4-(2-Amino-4-methyl-6-pentylamino-pyrimidin-5-ylmethyl)-phenol

A solution of BBr_3 (1M in DCM, 14.6 mL) was added to a solution of the product of Example 1 (2.30 g) in DCM at 0°C and stirred for 1 h. Ice and water were added and the mixture was stirred for 30 min, then the organic phase was separated, the aqueous layer was extracted with EtOAc, and the combined organics were dried and the solvent was removed by evaporation. The crude product was purified by FCC to give the title compound as a cream solid (1.11 g); ^1H NMR: 11.96 (1H, s), 7.57 (1H, s), 7.07 (2H, s), 6.93 (2H, d), 6.67 (2H, d), 3.69 (2H, s), 3.38-3.32 (2H, m), 2.16 (3H, s), 1.46 (2H, q), 1.27-1.18 (2H, m), 1.15-1.07 (2H, m), 0.82 (3H, t); LC-MS m/z 301.

Example 3: 5-(4-(2-(Dimethylamino)ethoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine

To a suspension of the product of Example 2 (0.10 g) in DMF (2.00 mL), Cs₂CO₃ (0.24 g) was added and stirred at r.t. for 30 min. A mixture of 2-dimethylaminoethylchloride hydrochloride (0.096 g), Cs₂CO₃ (0.24 g) and NaI (0.05 g) was also stirred for 30 min and the two mixtures combined and heated at 110°C for 2 h. The reaction was filtered, diluted with water, extracted with EtOAc, dried and the solvent removed. The crude product was purified by RPHPLC to afford the title compound as a colourless oil (0.035 g); ¹H NMR: 7.00 (2H, d), 6.81 (2H, d), 6.04 (1H, t), 5.62 (2H, s), 3.97 (2H, t), 3.65 (2H, s), 3.24 (2H, q), 2.57 (2H, t), 2.19 (6H, s), 2.01 (3H, s), 1.43 (2H, qn), 1.27-1.08 (4H, m), 0.81 (3H, t); LC-MS *m/z* 372.

Example 4: 5-(4-(3-(Dimethylamino)propoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 3 using dimethylamino-propylchloride hydrochloride (0.105g) to give the product as a colourless oil (0.039 g); ¹H NMR: 7.02 (2H, d), 6.81 (2H, d), 6.53 (1H, s), 6.10 (2H, s), 3.93 (2H, t), 3.68 (2H, s), 3.30-3.24 (2H, m), 2.53-2.48 (2H, m), 2.27 (6H, s), 2.06 (3H, s), 1.86 (2H, qn), 1.43 (2H, qn), 1.26-1.06 (4H, m), 0.81 (3H, t); LC-MS *m/z* 386.

Example 5: 6-Methyl-*N*⁴-pentyl-5-(4-(2-(piperidin-1-yl)ethoxy)benzyl)pyrimidine-2,4-diamine

The title compound was prepared by the method of Example 3 using *N*-(2-chloroethyl)-piperidine hydrochloride (0.12 g) to give the product as a white solid (0.058 g); ¹H NMR: 7.00 (2H, d), 6.81 (2H, d), 6.03 (1H, t), 5.61 (2H, s), 3.98 (2H, t), 3.65 (2H, s), 3.23 (2H, q), 2.60 (2H, t), 2.42-2.37 (4H, m), 2.01 (3H, s), 1.50-1.33 (8H, m), 1.26-1.18 (2H, m), 1.16-1.07 (2H, m), 0.81 (3H, t); LC-MS *m/z* 412.

Example 6: 6-Methyl-*N*⁴-pentyl-5-(4-(2-(pyrrolidin-1-yl)ethoxy)benzyl)pyrimidine-2,4-diamine

The title compound was prepared by the method of Example 3 using *N*-(2-chloroethyl)-pyrrolidine hydrochloride (0.115g) to give the product as a colourless oil (0.035 g).

¹H NMR: 7.00 (2H, d), 6.81 (2H, d), 6.04 (1H, t), 5.61 (2H, s), 3.99 (2H, t), 3.65 (2H, s), 3.24 (2H, q), 2.74 (2H, t), 2.37-2.20 (4H, m), 2.02 (3H, s), 1.69-1.63 (4H, m), 1.48-1.37 (2H, m), 1.27-1.08 (4H, m), 0.81 (3H, t); LC-MS *m/z* 398.

Example 7: 5-(4-(2-(Benzyl(methyl)amino)ethoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 3 using *N*-(2-chloroethyl)-*N*-methylbenzylamine hydrochloride (0.147 g) to give the product as a colourless oil (0.032 g); ¹H NMR: 7.35-7.18 (5H, m), 7.00 (2H, d), 6.81 (2H, d), 6.05 (1H, t), 5.62 (2H, s), 4.10-4.01 (2H, m), 3.65 (2H, s), 3.55 (2H, s), 3.24 (2H, q), 2.70 (2H, t), 2.21 (3H, s), 2.01 (3H, s), 1.43 (2H, qn), 1.27-1.09 (4H, m), 0.81 (3H, t); LC-MS *m/z* 448.

Example 8: 3-(4-((2-Amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenoxy)propan-1-ol

To a suspension of the product of Example 2 (0.35 g) in DMF (10.0 mL), Cs₂CO₃ (0.25 g) was added and the mixture was stirred at r.t. for 30 min. 3-Bromo-1-propanol (0.158 mL) and NaI (0.05 g) were added and the mixture was heated at 100°C for 9 h. The reaction was diluted with water, extracted with EtOAc, dried and the solvent removed. The crude product was purified by FCC eluting with 10:1 DCM-MeOH to afford the title compound as a colourless oil (0.24 g) which solidified upon standing; ¹H NMR: 7.00 (2H, d), 6.80 (2H, d), 6.05 (1H, t), 5.62 (2H, s), 4.50 (1H, t), 3.96 (2H, t), 3.64 (2H, s), 3.53 (2H, q), 3.24 (2H, q), 2.01 (3H, s), 1.82 (2H, qn), 1.43 (2H, qn), 1.28-1.17 (2H, m), 1.17-1.07 (2H, m), 0.82 (3H, t); LC-MS *m/z* 359.

Example 9: 6-Methyl-*N*⁴-pentyl-5-(4-(3-(pyrrolidin-1-yl)propoxy)benzyl)pyrimidine-2,4-diamine

(i) 5-(4-(3-Chloropropoxy)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine

To a solution the product of Example 8 (0.32 g) in DCM (5 mL), SOCl₂ (0.5 mL) was added and the solution was stirred at r.t. for 36 h. The solvent was removed and the crude material was purified by FCC eluting with DCM and then 20:1 DCM-MeOH to give the subtitle compound as an orange oil (0.124 g); ¹H NMR: 7.88 (1H, t), 7.07 (2H, d), 6.87 (2H, d), 4.04 (2H, t), 3.79-3.74 (4H, m), 3.36-3.25 (2H, m), 2.20 (3H, s), 2.17-2.10 (2H, m), 1.51-1.43 (2H, m), 1.27-1.15 (2H, m), 1.12-1.02 (2H, m), 0.80 (3H, t).

(ii) 6-Methyl-*N*⁴-pentyl-5-(4-(3-(pyrrolidin-1-yl)propoxy)benzyl)pyrimidine-2,4-diamine

To a suspension of triethylamine (0.09 mL), NaI (0.01 g) and the product of step (i) (0.04 g) in DMF (2 mL) was added pyrrolidine (0.027 mL). The mixture was heated at 80°C for 15 h, then cooled to r.t., diluted with water, extracted with EtOAc, dried and the solvent removed. The crude product was purified by RPHPLC to afford the title compound as an

orange oil (7 mg); ¹H NMR: 7.86 (s, 1H), 7.41 (s, 2H), 7.07 (d, 2H), 6.86 (d, 2H), 4.00 (t, 2H), 3.76 (s, 2H), 3.22 (t, 2H), 3.17 (s, 2H), 2.19 (s, 3H), 2.15-2.06 (m, 2H), 2.02-1.83 (m, 4H), 1.30-1.15 (m, 4H), 1.15-1.03 (m, 6H), 0.81 (t, 3H); LC-MS *m/z* 412.

Example 10: 6-Methyl-5-(4-(3-(4-methylpiperazin-1-yl)propoxy)benzyl)-N⁴-pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 9 step (ii) using the product of Example 9 step (i) (0.04 g) and 1-methylpiperazine (0.0354 mL) to give the product as a yellow oil (9 mg); ¹H NMR 7.00 (2H, d), 6.79 (2H, d), 6.02 (1H, t), 5.61 (2H, s), 3.92 (2H, t), 3.64 (2H, s), 3.23 (2H, q), 2.42-2.24 (10H, m), 2.13 (3H, s), 2.01 (3H, s), 1.81 (2H, qn), 1.42 (2H, qn), 1.28-1.16 (2H, m), 1.16-1.06 (2H, m), 0.81 (3H, t); LC-MS *m/z* 441.

Example 11: 5-(4-(3-(Dimethylamino)propoxy)-2-methoxybenzyl)-6-methyl-N⁴-pentylpyrimidine-2,4-diamine

(i) 4-(3-(Dimethylamino)propoxy)-2-methoxybenzaldehyde

3-Dimethylaminopropylchloride hydrochloride (2.493 g) and NaI (0.394 g) were added to 4-hydroxy-2-methoxybenzaldehyde (2 g) and Cs₂CO₃ (12.85 g) in DMF (50 mL). The resulting suspension was stirred at 100°C for 1 h. The reaction mixture was filtered and diluted with EtOAc (100 mL). The organic phase was washed with water and brine, dried, filtered and concentrated by evaporation to afford the subtitle compound as a yellow oil (2.23 g); ¹H NMR: 10.17 (1H, s), 7.65 (1H, d), 6.67 (1H, d), 6.64 (1H, dd), 4.12 (2H, t), 3.90 (3H, s), 2.35 (2H, t), 2.14 (6H, s), 1.87 (2H, qn).

(ii) Ethyl 2-(4-(3-(dimethylamino)propoxy)-2-methoxybenzylidene)-3-oxobutanoate

Ethyl acetoacetate (1.489 mL), piperidine (0.047 mL) and acetic acid (0.145 mL) were added to a solution of the product from step (i) (2.23 g) in toluene (50 mL), and the mixture was stirred at 110°C for 5 days. The solvent was removed under reduced pressure to afford the subtitle compound (3.57 g) that was used in the next step without purification.

(iii) Ethyl 2-(4-(3-(dimethylamino)propoxy)-2-methoxybenzyl)-3-oxobutanoate

A suspension of the product from step (ii) (3.57 g) and 10% Pd/C (0.2 g) in EtOH (50 mL) was hydrogenated under 3 bar at r.t. for 16 h. The reaction mixture was filtered through diatomaceous earth (CeliteTM) and the filtrate was concentrated by evaporation. The crude product was purified by FCC eluting with 0-10% MeOH in EtOAc to afford the subtitle compound (1.25 g) as a yellow oil; ¹H NMR: 6.95 (1H, d), 6.51 (1H, d), 6.40 (1H, dd),

4.10-4.00 (2H, m), 3.96 (2H, t), 3.83 (1H, t), 3.77 (3H, s), 3.01-2.81 (2H, m), 2.34 (2H, t), 2.14 (9H, s), 1.82 (2H, qn), 1.12 (3H, t).

(iv) 2-Amino-5-(4-(3-(dimethylamino)propoxy)-2-methoxybenzyl)-6-methylpyrimidin-4-ol

5 Guanidine carbonate (0.716 g) was added in one portion to a solution of the product from step (iii) (1.25 g) in EtOH (20 mL) and the mixture was stirred at 80°C for 15 h. The solvent was evaporated, the residue diluted with EtOAc (20 mL), washed with water, dried and evaporated. The residue was suspended in hexane-EtOAc (5:1; 20 mL) and the solid was collected by filtration to afford the subtitle compound as a pale yellow solid (0.87 g);
10 ¹H NMR: 6.72 (d, 1H), 6.60 (s, 2H), 6.48 (d, 1H), 6.35 (dd, 1H), 3.93 (t, 2H), 3.78 (s, 3H), 3.46 (s, 2H), 2.33 (t, 2H), 2.13 (s, 6H), 1.90 (s, 3H), 1.84-1.78 (m, 2H).

(v) 4-Chloro-5-(4-(3-(dimethylamino)propoxy)-2-methoxybenzyl)-6-methylpyrimidin-2-amine

The subtitle compound was prepared using the method of Example 1 step (iii) and the
15 product of step (iv) to give a tan solid (0.71 g); ¹H NMR: 6.83 (s, 2H), 6.57 (d, 1H), 6.54 (d, 1H), 6.41 (dd, 1H), 4.00 (t, 2H), 3.81 (s, 3H), 3.75 (s, 2H), 3.05-2.95 (m, 2H), 2.63 (s, 6H), 2.15 (s, 3H), 2.11-2.01 (m, 2H).

(vi) 5-(4-(3-(Dimethylamino)propoxy)-2-methoxybenzyl)-6-methyl-N⁴-pentylpyrimidine-2,4-diamine

20 Amylamine (0.127 mL) was added to a solution of the product from step (v) (100 mg) in NMP (2 mL) and stirred at 150°C for 15 h. The mixture was diluted with EtOAc (10 mL) washed with sat. NaHCO₃ (10 mL), water (10 mL), and sat. brine (10 mL) dried, and the solvent removed by evaporation. The crude product was purified by RPHPLC and then trituration with diethyl ether gave the title compound as a white solid (8 mg); ¹H NMR:
25 6.60 (d, 1H), 6.53 (d, 1H), 6.37 (dd, 1H), 5.86 (t, 1H), 5.61 (s, 2H), 3.93 (t, 2H), 3.82 (s, 3H), 3.52 (s, 2H), 3.21 (q, 2H), 2.35-2.30 (m, 2H), 2.12 (s, 6H), 1.98 (s, 3H), 1.80 (q, 2H), 1.46-1.36 (m, 2H), 1.28-1.18 (m, 2H), 1.17-1.08 (m, 2H), 0.82 (t, 3H); LC-MS *m/z* 416.

The title compound can also be made by the following method:

Methanesulfonyl chloride (0.040 mL) was added to the mixture of the product from

30 Example 36 (0.17 g) and triethylamine (0.072 mL) in THF (5 mL) at 0°C and the mixture was stirred for 30 min. Sat. NaHCO₃ was added and the mixture was extracted twice with CHCl₃, then the combined organic layers were dried and concentrated. The residue was

dissolved in DMF (5 mL), then dimethylamine (40% aq. solution, 2 mL) was added and the mixture was stirred at r.t. for 18 h. The mixture was then treated with 4% NH₃ solution and brine and extracted twice with EtOAc. The combined organic layers were washed twice with brine, dried and concentrated. The residue was purified by FCC to give the title compound as a white solid (0.10 g); ¹H NMR: 6.61 (d, 1H), 6.53 (d, 1H), 6.37 (dd, 1H), 6.18 (br t, 1H), 5.91 (brs, 2H), 3.94 (t, 2H), 3.82 (s, 3H), 3.53 (s, 2H), 3.22 (q, 2H), 2.42 (t, 2H), 2.20 (s, 6H), 2.00 (s, 3H), 1.85 (tt, 2H), 1.42 (tt, 2H), 1.24 (m, 2H), 1.13 (m, 2H), 0.82 (t, 3H); LC-MS *m/z* 415 ESI.

Example 12: Methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxybenzoate

(i) Methyl 4-(2-(ethoxycarbonyl)-3-oxobutyl)-3-methoxybenzoate

NaH (60% in mineral oil, 1.45 g) was added portionwise over 10 min to a solution of ethyl acetoacetate (4.4 mL) in THF (60 mL) at 0°C and the mixture was stirred for 10 min. A solution of methyl 4-(bromomethyl)-3-methoxybenzoate (7.5 g) in THF (40 mL) was added and the mixture was warmed to 70°C and stirred for 15 h. The reaction was poured into ice/water (300 mL) and stirred for 30 min. The aqueous mixture was extracted with EtOAc, dried and concentrated by evaporation to afford the subtitle compound. The reaction was repeated on an identical scale. The two batches of crude product were combined and purified by FCC eluting with 8:2 to 7:3 isohexane-EtOAc to afford the subtitle compound as a colourless oil (14.7 g); ¹H NMR: 7.48 (dd, 1H), 7.45 (d, 1H), 7.24 (d, 1H), 4.05 (q, 2H), 3.95 (dd, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.10 (dd, 1H), 3.00 (dd, 1H), 2.17 (s, 3H), 1.09 (t, 3H).

(ii) Methyl 4-((2-amino-4-hydroxy-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate

The subtitle compound was formed using the method of Example 1 step (ii) and the product from step (i) (14.7 g) to give the subtitle compound as a colourless solid (8.6 g), which was used without further purification; ¹H NMR: 10.78 (s, 1H), 7.46 (d, 1H), 7.45 (s, 1H), 6.98 (d, 1H), 6.34 (s, 2H), 3.89 (s, 3H), 3.83 (s, 3H), 3.61 (s, 2H), 1.93 (s, 3H); LC-MS *m/z* 304.

(iii) Methyl 4-((2-amino-4-chloro-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate

The subtitle compound was formed using the method of Example 1 step (iii) and the product from step (ii) (8.6 g) to give the subtitle compound as a colourless solid (9.05 g),

which was used without further purification; ^1H NMR: 7.50 (s, 2H), 7.49 (d, 1H), 6.90 (s, 1H), 6.81 (d, 1H), 3.92 (s, 3H), 3.90 (s, 3H), 3.84 (s, 2H), 2.16 (s, 3H).

(iv) Methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxybenzoate

- 5 Pentylamine (7.22 mL) was added to a solution of the product of step (iii) (5 g) in NMP (80 mL) and the mixture was stirred at 150°C for 15 h. The reaction mixture was cooled, diluted with EtOAc (200 mL), washed with water (3×200 mL), brine (100 mL), dried and concentrated by evaporation. The residue was suspended in diethyl ether (20 mL) and the solid produced was collected by filtration to give the title compound as a colourless solid
- 10 (1.21 g); ^1H NMR 7.48 (d, 1H), 7.45 (dd, 1H), 6.81 (d, 1H), 6.07 (t, 1H), 5.68 (s, 2H), 3.92 (s, 3H), 3.83 (s, 3H), 3.68 (s, 2H), 3.25-3.20 (m, 2H), 1.93 (s, 3H), 1.47-1.38 (m, 2H), 1.27-1.08 (m, 4H), 0.81 (t, 3H); LC-MS m/z 373.

Example 13: (S)-Methyl 4-((2-amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate

- 15 (S)-Methyl 4-((2-amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate
- (S)-2-Aminopentan-1-ol (0.769 g) was added to a solution of the product from Example 12 step (iii) (1.2 g) in NMP (20 mL) and the mixture was stirred at 120°C for 60 h. The reaction mixture was then cooled, diluted with EtOAc (50 mL), washed with saturated
- 20 NaHCO_3 (2×50 mL), brine (50 mL), dried and concentrated by evaporation. The crude product was purified by FCC eluting with 20:1 to 10:1 DCM-MeOH to produce an orange oil (0.475 g). A 100 mg sample was further purified by RPHPLC to give the title compound as an orange gum (15 mg); ^1H NMR: 7.48 (d, 1H), 7.46 (dd, 1H), 6.89 (d, 1H), 5.68 (s, 2H), 5.50 (d, 1H), 4.58-4.48 (m, 1H), 4.17-4.05 (m, 1H), 3.92 (s, 3H), 3.84 (s, 3H),
- 25 3.70 (s, 2H), 3.39-3.20 (m, 2H), 1.99 (s, 3H), 1.54-1.39 (m, 1H), 1.33-1.20 (m, 1H), 1.16-1.02 (m, 2H), 0.76 (t, 3H); LC-MS m/z 389.

Example 14: (S)-Methyl 4-((2-amino-4-(1-hydroxyheptan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate

- 30 (i) (E)-tert-Butyl hept-2-enoate

To a solution of valeraldehyde (5.81 g) in THF (100 mL) was added *tert*-butoxycarbonylmethylenetriphenylphosphorane (25.4 g) and the mixture was stirred for 16 h at r.t. The

solvents were removed by evaporation and the resulting residue was slurried in diethyl ether and then the mixture was filtered. The filtrate was concentrated by evaporation and the residue was purified by FCC eluting with 97:3 isohexane-EtOAc to give the subtitle compound (8.5 g); ¹H NMR (CDCl₃): 6.86 (dt, 1H), 5.73 (dt, 1H), 2.25-2.09 (m, 2H), 1.47 (s, 9H), 1.47-1.27 (m, 4H), 0.90 (t, 3H).

(ii) (S)-tert-Butyl 3-(benzyl((S)-1-phenylethyl)amino)heptanoate

n-Butyllithium (2.5 M in hexanes, 27.66 mL) was added to a stirred solution of (S)-*N*-benzyl-1-phenylethanamine (15.59 g) in THF (150 mL) at -78°C. The reaction mixture was stirred for 30 min then the product from step (i) (8.5 g) in THF (50 mL) was added and the reaction mixture was stirred for 2h at -78°C. The mixture was quenched with sat. NH₄Cl solution and warmed to r.t. The mixture was partitioned between EtOAc and water, the organic phase was washed with water, dried, and concentrated by evaporation. The residue was purified by FCC eluting with 95:5 isohexane-EtOAc to give the subtitle compound (12.7g); ¹H NMR (CDCl₃): 7.49-7.15 (m, 10H), 3.87-3.70 (m, 2H), 3.48 (d, 1H), 3.35-3.21 (m, 1H), 1.99-1.78 (m, 2H), 1.53 (s, 3H), 1.39 (s, 9H), 1.36-1.14 (m, 6H), 0.88 (t, 3H); LC-MS *m/z* 396 ESI.

(iii) (S)-3-(Benzyl((S)-1-phenylethyl)amino)heptanoic acid

The product from step (ii) (12 g) was dissolved in DCM (40 mL) and trifluoroacetic acid (2 mL) and the resulting mixture was stirred for 24 h. The solvents were removed by evaporation to give the subtitle compound (17 g); LC-MS *m/z* 340 ESI.

(iv) (S)-3-(Benzyl((S)-1-phenylethyl)amino)heptan-1-ol

The product from step (iii) (12 g) was dissolved in THF (120 mL) and borane-THF complex (1 M in THF, 132.3 mL) was added dropwise. The mixture was then stirred at r.t. overnight then MeOH was added followed by 2 M HCl (20 mL). The mixture was concentrated by evaporation and the resulting residue was dissolved in MeOH and purified *via* SCX resin. The resulting residue was further purified *via* FCC eluting with 9:1 to 4:1 isohexane-EtOAc to give the subtitle compound (6 g); ¹H NMR (CDCl₃): 7.45-7.13 (m, 10H), 4.00-3.91 (m, 1H), 3.85 (d, 1H), 3.69 (d, 1H), 3.56-3.43 (m, 1H), 3.27-3.15 (m, 1H), 2.84-2.71 (m, 1H), 2.61 (s, 1H), 1.77-1.63 (m, 1H), 1.55 (s, 2H), 1.47-1.20 (m, 8H), 0.93 (t, 3H); LC-MS *m/z* 326 ESI.

(v) (S)-3-Aminoheptan-1-ol

A solution of the product from step (iv) (5 g) and 5% Pd/C (0.5 g) in EtOH (25 mL) was hydrogenated using a pressure of 5 bar at r.t. for 5 days. A further portion of 5% Pd/C (1.50 g) was then added, and the mixture was hydrogenated using a pressure of 5 bar at r.t. for a further 1 day. The reaction mixture was then filtered and the solvent removed by evaporation to give the subtitle compound (1.8 g); ¹H NMR (CDCl₃): 3.89-3.74 (m, 2H), 2.94-2.84 (m, 1H), 2.79-2.41 (m, 3H), 1.70-1.60 (m, 1H), 1.55-1.38 (m, 2H), 1.39-1.19 (m, 5H), 0.96-0.83 (m, 3H).

(vi) (S)-Methyl 4-((2-amino-4-(1-hydroxyheptan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate

The title compound was prepared by the method of Example 13 using the product from Example 12 step (iii) (0.1 g) and the product of step (v) (0.08 g). The crude product was purified by RPHPLC to give the title compound as a colourless gum (9 mg); ¹H NMR: 7.49 (d, 1H), 7.46 (dd, 1H), 6.90 (d, 1H), 6.44-6.25 (m, 2H), 4.39-4.33 (m, 1H), 4.29-4.20 (m, 1H), 3.93 (s, 3H), 3.84 (s, 3H), 3.74 (s, 2H), 3.30-3.28 (m, 2H), 2.03 (s, 3H), 1.66-1.47 (m, 2H), 1.47-1.32 (m, 2H), 1.29-0.97 (m, 4H), 0.76 (t, 3H); LC-MS *m/z* 417.

Example 15: (S)-4-(Dimethylamino)butyl 4-((2-amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate benzenesulfonate salt
(i) (S)-4-((2-Amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoic acid

(S)-2-Amino-1-pentanol (192 mg) was added to a stirred suspension of the product of Example 12 step (iii) (0.30 g) in butan-1-ol (2 mL) and the mixture was heated in a microwave at 180°C for 2 h. 5M KOH (0.5 mL) was added and the mixture was then heated to 120°C over a period of 1 h in a microwave. The mixture was then concentrated by evaporation and the residue was diluted with MeOH (2 mL). Glacial acetic acid was added dropwise until the pH ~ 7 and the mixture was then purified by RPHPLC to give the subtitle compound as a colourless solid (53 mg); ¹H NMR: 7.47 (d, 1H), 7.41 (dd, 1H), 6.85 (d, 1H), 5.74 (s, 2H), 5.52 (d, 1H), 4.15-4.06 (m, 1H), 3.90 (s, 3H), 3.68 (s, 2H), 3.38-3.33 (m, 1H), 3.28-3.22 (m, 1H), 2.02 (s, 3H), 1.52-1.41 (m, 1H), 1.32-1.21 (m, 3H), 1.15-1.03 (m, 2H), 0.76 (t, 3H); LC-MS *m/z* 375.

(ii) (S)-4-(Dimethylamino)butyl 4-((2-amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoate benzene sulphonate

A solution of 1-propanephosphonic acid cyclic anhydride (0.35 mL) (1.57 M in THF) was added to a suspension of the product of step (i) (69 mg), triethylamine (0.077 mL), 4-(dimethylamino)-1-butanol (0.12 mL) and 4-dimethylaminopyridine (4.50 mg) in DMF (2 mL). The mixture was stirred at r.t. for 60 h and was then diluted with EtOAc (10 mL).

5 The solution was washed with water (2 × 10 mL) dried and concentrated by evaporation. The crude product was purified by RPHPLC to produce a colourless gum which was dissolved in MeCN (0.5 mL). Benzenesulphonic acid (7.9 mg) was added and the solvent was evaporated to give a residue which was triturated with diethyl ether to give the title compound as a colourless solid (27.0 mg); ¹H NMR: 7.61-7.58 (m, 1H), 7.48-7.45 (m, 3H), 7.34-7.27 (m, 5H), 6.93 (d, 1H), 6.21-6.06 (m, 1H), 4.63-4.57 (m, 1H), 4.27 (t, 2H), 4.20-4.12 (m, 1H), 3.92 (s, 3H), 3.73 (s, 2H), 3.41-3.33 (m, 4H), 2.42 (s, 6H), 2.03 (s, 3H), 1.77-1.67 (m, 2H), 1.66-1.57 (m, 1H), 1.53-1.43 (m, 1H), 1.34-1.21 (m, 2H), 1.15-1.03 (m, 2H), 0.77 (t, 3H); LC-MS *m/z* 474.

Example 16: Methyl 3-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-4-methoxybenzoate

(i) Methyl 3-(bromomethyl)-4-methoxybenzoate

Methyl 4-methoxy-3-methylbenzoate (16 g) was dissolved in EtOAc (100 mL) and then *N*-bromosuccinimide (18.96 g) and 2,2'-azobisisobutyronitrile (1 g) were added. The mixture was then heated to 80°C for 4 h. After cooling to r.t. sat. sodium thiosulfate solution was added, the organic phase was separated, washed with brine, dried and the solvents removed by evaporation. The crude product was dissolved in mixture of isohexane-EtOAc (9:1) and a solid was produced which was collected to give the subtitle compound (11.82 g); ¹H NMR (CDCl₃): 8.05-7.98 (m, 2H), 6.91 (d, 1H), 4.55 (s, 2H), 3.96 (s, 3H), 3.89 (s, 3H). LC-MS *m/z* 260.

(ii) Methyl 3-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-4-methoxybenzoate

The title compound was prepared using the product from step (i) (11.82 g) and the method of Example 12 steps (i)-(iv) to give a solid product (2.0 g); ¹H NMR: 7.83 (d, 1H), 7.32 (s, 1H), 7.11 (d, 1H), 6.08 (s, 1H), 5.69 (s, 2H), 3.94 (s, 3H), 3.73 (s, 3H), 3.63 (s, 2H), 3.25-3.07 (m, 2H), 1.93 (s, 3H), 1.50-1.33 (m, 2H), 1.25-1.01 (m, 4H), 0.79 (t, 3H); LC-MS *m/z* 373.

Example 17: Methyl 3-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-4-fluorobenzoate

(i) Methyl 4-fluoro-3-methylbenzoate

SOCl₂ (5.68 mL) was added dropwise to a solution of 4-fluoro-3-methylbenzoic acid (10 g) in MeOH (150 mL) at 0°C over a period of 10 mins. under N₂. The resulting mixture was stirred at r.t. for 24 h and then the solvent was removed by evaporation. The residue was dissolved in EtOAc, washed with sat. NaHCO₃, sat. brine, dried and then concentrated by evaporation to afford the subtitle compound (9.85 g); ¹H NMR: 7.93-7.83 (m, 2H), 7.04 (dd, 1H), 3.90 (s, 3H), 2.31 (s, 3H).

(ii) Methyl 3-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-4-fluorobenzoate

The title compound was prepared using the product from step (i) (12.8 g) and the method of Example 12 steps (i)-(iv) to give a colourless solid (0.27 g); ¹H NMR: 7.89-7.81 (m, 1H), 7.46 (dd, 1H), 7.32 (dd, 1H), 6.31 (t, 1H), 5.74 (s, 2H), 3.78 (s, 3H), 3.77 (s, 2H), 3.27-3.22 (m, 2H), 1.95 (s, 3H), 1.44 (qn, 2H), 1.27-1.07 (m, 4H), 0.79 (t, 3H); LC-MS *m/z* 361.

Example 18: Methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-fluorobenzoate

(i) Methyl 4-(bromomethyl)-3-fluorobenzoate

The subtitle compound was prepared from 3-fluoro-4-methylbenzoic acid (15 g) by the method of Example 17 step (i) to give the product (14.5 g) as an orange oil; ¹H NMR: 7.70 (dd, 1H), 7.62 (dd, 1H), 7.45 (dd, 1H), 3.85 (s, 3H), 2.31 (d, 3H).

(ii) Methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-fluorobenzoate

The title compound was prepared using the product from step (i) (12.8 g) and the method of Example 12 steps (i)-(iv) to give a colourless solid (40 mg); ¹H NMR: 7.70-7.63 (m, 2H), 6.97 (dd, 1H), 6.53-6.41 (m, 1H), 6.00 (s, 2H), 3.84 (s, 3H), 3.81 (s, 2H), 3.28-3.21 (m, 2H), 1.97 (s, 3H), 1.44 (qn, 2H), 1.29-1.07 (m, 4H), 0.81 (t, 3H); LC-MS *m/z* 361.

Example 19: 5-(2-Methoxybenzyl)-6-methyl-N4-pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 1 from 2-methoxybenzaldehyde (10 g) to give the product as a light brown solid (0.74 g); ¹H NMR: 7.19

(1H, td), 7.00 (1H, d), 6.86-6.73 (2H, m), 6.03-5.90 (1H, m), 5.76 (2H, s), 3.86 (3H, s), 3.65 (2H, s), 3.29-3.16 (2H, m), 2.02 (3H, s), 1.51-1.39 (2H, m), 1.31-1.12 (4H, m), 0.84 (3H, t); LC-MS m/z 315.

Example 20: 2-((2-Amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenol

5 Prepared by the method of Example 2 using the product of Example 19 (0.6 g) to give the product as a colourless solid (0.52 g); ^1H NMR: 11.87 (1H, s), 7.89 (1H, t), 7.34 (2H, s), 7.05 (1H, t), 6.88-6.78 (2H, m), 6.74-6.68 (1H, m), 3.67 (2H, s), 3.37 (2H, q), 2.20 (3H, s), 1.49 (2H, qn), 1.29-1.11 (4H, m), 0.82 (3H, t); LC-MS m/z 301.

Example 21: 5-(2-Ethoxybenzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

10 A suspension of the product of Example 20 (0.1 g) and Cs_2CO_3 (0.5 g) in DMF (2 mL) was stirred for 30 mins. Bromoethane (0.03 mL) was then added and the resulting suspension was heated at 80°C for 1 h. The mixture was then cooled, filtered and EtOAc (10 mL) and water (5 mL) were added. The organic phase was separated, dried and concentrated to give a crude product which was purified by RPHPLC to give the title compound as a colourless
15 solid (27 mg); ^1H NMR: 7.13 (1H, td), 6.96 (1H, d), 6.82-6.74 (2H, m), 5.93 (1H, t), 5.62 (2H, s), 4.09 (2H, q), 3.62 (2H, s), 3.23 (2H, q), 1.99 (3H, s), 1.41 (2H, qn), 1.39 (3H, t), 1.28-1.08 (4H, m), 0.82 (3H, t); LC-MS m/z 329.

Example 22: 5-(2-(3-(Dimethylamino)propoxy)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

20 The title compound was prepared by the method of Example 3 using the product of Example 20 (0.1g) and N,N -dimethylaminopropylchloride hydrochloride (0.105 g) to give a colourless solid (27 mg); ^1H NMR: 7.14 (1H, td), 6.96 (1H, d), 6.81-6.74 (2H, m), 5.92 (1H, t), 5.63 (2H, s), 4.05 (2H, t), 3.63 (2H, s), 3.23 (2H, q), 2.41 (2H, t), 2.15 (6H, s), 1.99 (3H, s), 1.90 (2H, qn), 1.42 (2H, qn), 1.28-1.17 (2H, m), 1.17-1.07 (2H, m), 0.81 (3H, t);
25 LC-MS m/z 386.

Example 23: 5-(3-Methoxybenzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 1 from 3-methoxybenzaldehyde (10 g) to give a light brown solid (3.7 g); ^1H NMR: 7.16 (1H, dd), 6.75-6.66
30 (3H, m), 6.30 (1H, s), 5.82 (2H, s), 3.72 (2H, s), 3.70 (3H, s), 3.30-3.23 (2H, m), 2.03 (3H, s), 1.49-1.39 (2H, m), 1.29-1.08 (4H, m), 0.82 (3H, t); LC-MS m/z 315.

Example 24: 3-((2-Amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenol

The title compound was prepared by the method of Example 2 using the product of Example 23 (0.9 g) to give a light brown solid (0.72 g); ¹H NMR: 9.25 (1H, s), 7.20-6.93 (2H, m), 6.65 (2H, s), 6.60-6.53 (2H, m), 6.50 (1H, s), 3.71 (2H, s), 3.43-3.20 (2H, m), 2.10 (3H, s), 1.46 (2H, qn), 1.31-1.06 (4H, m), 0.82 (3H, t); LC-MS *m/z* 301.

Example 25: 5-(3-(3-(Dimethylamino)propoxy)benzyl)-6-methyl-N⁴-pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 3 using the product of Example 24 (0.1 g) and *N,N*-dimethylaminopropylchloride hydrochloride (0.105 g) to give a colourless solid (0.054 g); ¹H NMR: 7.14 (1H, dd), 6.72-6.64 (3H, m), 6.10 (1H, t), 5.63 (2H, s), 3.92 (2H, t), 3.69 (2H, s), 3.25 (2H, q), 2.31 (2H, t), 2.12 (6H, s), 2.01 (3H, s), 1.80 (2H, qn), 1.43 (2H, qn), 1.28-1.19 (2H, m), 1.18-1.09 (2H, m), 0.82 (3H, t); LC-MS *m/z* 386.

Example 26: 6-Methyl-N⁴-pentyl-5-(3-(2-(piperidin-1-yl)ethoxy)benzyl)pyrimidine-2,4-diamine

The title compound was prepared by the method of Example 3 using the product of Example 24 (0.1 g) and *N*-2-chloroethylpiperidinehydrochloride (0.122 g) to give a colourless oil (0.045 g); ¹H NMR: 7.14 (1H, dd), 6.74-6.65 (3H, m), 6.09 (1H, t), 5.63 (2H, s), 3.98 (2H, t), 3.69 (2H, s), 3.24 (2H, q), 2.60 (2H, t), 2.42-2.37 (4H, m), 2.01 (3H, s), 1.51-1.33 (8H, m), 1.27-1.19 (2H, m), 1.17-1.10 (2H, m), 0.81 (3H, t); LC-MS *m/z* 412.

Example 27: 5-(3-(2-(Dimethylamino)ethoxy)benzyl)-6-methyl-N⁴-pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 3 using the product of Example 24 (0.1 g) and *N*-2-dimethylaminochloride hydrochloride (0.096 g) to give a light brown solid (0.022 g); ¹H NMR: 7.15 (1H, dd), 6.72 (1H, d), 6.69-6.65 (2H, m), 6.10 (1H, t), 5.63 (2H, s), 3.97 (2H, t), 3.69 (2H, s), 3.25 (2H, q), 2.58 (2H, t), 2.19 (6H, s), 2.01 (3H, s), 1.43 (2H, qn), 1.29-1.09 (4H, m), 0.82 (3H, t); LC-MS *m/z* 372.

Example 28: 6-Methyl-N⁴-pentyl-5-(3-(2-(pyrrolidin-1-yl)ethoxy)benzyl)pyrimidine-2,4-diamine

The title compound was prepared by the method of Example 3 using the product of Example 24 (0.1 g) and *N*-2-chloroethylpyrrolidine hydrochloride (0.115 g) to give a

colourless oil (0.036 g); ¹H NMR: 7.15 (1H, dd), 6.74-6.65 (3H, m), 6.11 (1H, s), 5.65 (2H, s), 3.99 (2H, t), 3.70 (2H, s), 3.27-3.22 (2H, m), 2.74 (2H, t), 2.44-2.36 (4H, m), 2.02 (3H, s), 1.71-1.63 (4H, m), 1.44 (2H, qn), 1.30-1.19 (2H, m), 1.18-1.10 (2H, m), 0.82 (3H, t); LC-MS *m/z* 398.

5 **Example 29: 5-(3-((Dimethylamino)methyl)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine**

(i) Ethyl 2-(3-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate

The method of Example 12 using methyl 3-bromomethylbenzoate (6 g) was used to provide the subtitle compound as an orange oil which solidified on standing (0.7 g); ¹H NMR: 7.79-7.71 (2H, m), 7.45-7.32 (2H, m), 6.36 (1H, s), 5.78 (2H, s), 4.29 (2H, q), 3.82 (2H, s), 3.29-3.22 (2H, m), 2.01 (3H, s), 1.49-1.38 (2H, m), 1.28-1.07 (7H, m), 0.79 (3H, t).

(ii) (3-((2-Amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)methanol

A solution of the product of step (i) (0.21 g) in THF (2 mL) was added to a solution of LiAlH₄ (1M in THF, 0.88 mL) in THF (2 mL) at 0°C. The mixture was stirred at r.t. for 2 h. A further portion of LiAlH₄ (0.88 mL) was then added and the mixture was stirred at r.t. for 15 h. The mixture was then poured cautiously into 2M NaOH (20 mL) and the aqueous phase was extracted with EtOAc (3 × 20 mL). The combined organic phase was dried and concentrated by evaporation to give the subtitle compound as a colourless solid which was used without further purification (0.176 g); ¹H NMR: 7.19 (1H, dd), 7.09 (2H, d), 7.07 (2H, s), 6.97 (1H, d), 6.12 (1H, t), 5.10 (1H, t), 4.43 (2H, d), 3.72 (2H, s), 3.24 (2H, q), 2.01 (3H, s), 1.44 (2H, qn), 1.28-1.10 (4H, m), 0.82 (3H, t).

(iii) 5-(3-(Chloromethyl)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine

SOCl₂ (0.049 mL) was added to a stirred solution of the product from step (ii) (0.176 g) in DCM (5 mL) at r.t. The mixture was stirred for 1 h, then the solvent was removed to give the subtitle compound as a yellow oil that was used without further purification (0.182 g); ¹H NMR: 7.97 (1H, t), 7.34-7.25 (3H, m), 7.21 (2H, s), 7.15-7.09 (1H, m), 4.72 (2H, s), 3.86 (2H, s), 3.37 (2H, q), 2.19 (3H, s), 1.47 (2H, qn), 1.27-1.17 (2H, m), 1.15-1.06 (2H, m), 0.80 (3H, t).

30 **(iv) 5-(3-((Dimethylamino)methyl)benzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine**

2M Dimethylamine solution in EtOH (0.4 mL) was added to a solution of the product of step (iii) (0.09 g) in DMF (2 mL) and the mixture was stirred at r.t. for 15 h. Sat NaHCO₃

was then added and the aqueous phase was extracted with EtOAc (2×10 mL). The combined organic phases were washed with water (3×5 mL), dried and concentrated to a residue which was purified by RPHPLC to give the title compound as an off white solid (44 mg); ^1H NMR: 7.19 (1H, dd), 7.07-7.03 (2H, m), 6.98 (1H, d), 6.13 (1H, s), 5.63 (2H, s), 3.72 (2H, s), 3.29 (2H, s), 3.24 (2H, q), 2.10 (6H, s), 2.00 (3H, s), 1.43 (2H, qn), 1.27-1.20 (2H, m), 1.18-1.10 (2H, m), 0.82 (3H, t); LC-MS m/z 342.

Example 30: 5-(4-(3-(Dimethylamino)prop-1-ynyl)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

(i) 5-(4-Iodobenzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

The method of Example 12 using 4-iodobenzylbromide and ethylacetoacetate was used to provide the subtitle compound as a solid (60mg); ^1H NMR: 7.59 (2H, d), 6.91 (2H, d), 6.16-6.09 (1H, m), 5.69-5.63 (2H, m), 3.69 (2H, s), 3.27-3.18 (2H, m), 1.99 (3H, s), 1.46-1.37 (2H, m), 1.28-1.06 (4H, m), 0.82 (3H, t); LC-MS m/z 411.

(ii) 5-(4-(3-(Dimethylamino)prop-1-ynyl)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

1-Dimethylamino-2-propyne (24 mg) was dissolved in THF (2 mL) purged with nitrogen and CuI (4.64 mg) was added. The mixture was stirred for 30 mins. and added to a suspension of the product of step (i) (0.1 g) and $\text{Pd}(\text{PPh}_3)_4$ (14.08 mg) in a 1:1 mixture of THF and triethylamine (2 mL). The reaction mixture was then heated to 100°C for 16 h, cooled and concentrated by evaporation. The residue was purified by RPHPLC to give the title compound as a solid (9 mg); ^1H NMR: 7.31 (2H, d), 7.09 (2H, d), 6.16-6.11 (1H, m), 5.65 (2H, s), 3.74 (2H, s), 3.41 (2H, s), 2.22 (6H, s), 2.00 (3H, s), 1.46-1.40 (2H, m), 1.27-1.16 (4H, m), 1.14-1.06 (2H, m), 0.81 (3H, t); LC-MS m/z 366.

Example 31: 5-(4-(3-(Dimethylamino)propyl)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

The product of Example 30 (8 mg) was dissolved in EtOH and hydrogenated in a H-cubeTM hydrogenator using a 10% Pt/C reaction cartridge (available from ThalesNano Nanotechnology, Hungary) using the "full H_2 mode". The solvent was removed by evaporation and the resulting residue was purified *via* RPHPLC to give the title compound as a solid (1 mg); ^1H NMR: 7.06 (2H, d), 7.00 (2H, d), 6.09-6.03 (1H, m), 5.62 (2H, s), 3.68 (2H, s), 3.25-3.19 (2H, m), 2.19-2.13 (2H, m), 2.09 (6H, s), 2.00 (3H, s), 1.66-1.59

(2H, m), 1.46-1.38 (2H, m), 1.25-1.17 (4H, m), 1.16-1.08 (2H, m), 0.81 (3H, t); LC-MS m/z 370.

Example 32: 5-(3-(3-(Dimethylamino)propyl)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

5 **(i) 5-(3-(3-(Dimethylamino)prop-1-ynyl)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine**

The method of Example 30 using 3-iodobenzyl bromide was used to provide the subtitle compound (60 mg); LC-MS m/z 366.

(ii) 5-(3-(3-(Dimethylamino)propyl)benzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

10 The method of Example 31 using the product from step (i) (0.06 g) was used to provide the subtitle compound as a solid (8 mg); ^1H NMR: 7.15 (1H, t), 7.00-6.89 (3H, m), 6.12-6.06 (1H, m), 5.62 (2H, s), 3.70 (2H, s), 3.29 (2H, s), 3.28-3.21 (2H, m), 2.18-2.13 (2H, m), 2.08 (6H, s), 2.01 (3H, s), 1.69-1.57 (2H, m), 1.49-1.38 (2H, m), 1.27-1.18 (2H, m), 1.18-1.07 (2H, m), 0.82 (3H, t); LC-MS m/z 370.

15 **Example 33: 5-(4-(3-(Dimethylamino)propoxy)-2-methylbenzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine**

(i) 5-(4-Methoxy-2-methylbenzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

The method of Example 1 using 4-methoxy-2-methylbenzaldehyde (10 g) was used to provide the subtitle compound as a cream solid (0.67 g); ^1H NMR: 6.77 (d, 1H), 6.59 (dd, 1H), 6.49 (d, 1H), 5.97 (t, 1H), 5.63 (s, 2H), 3.68 (s, 3H), 3.52 (s, 2H), 3.22 (q, 2H), 2.32 (s, 3H), 1.90 (s, 3H), 1.42 (qn, 2H), 1.29-1.09 (m, 4H), 0.82 (t, 3H).

(ii) 4-((2-Amino-4-(pentylamino)pyrimidin-5-yl)methyl)-3-methylphenol

The method of Example 2 using the product of step (i) (0.5 g) was used to provide the subtitle compound as a colourless solid that was used without purification (0.350 g); ^1H NMR: 8.96 (s, 1H), 6.58 (s, 1H), 6.48-6.30 (m, 2H), 5.95 (s, 1H), 5.62 (s, 2H), 3.48 (s, 2H), 3.22 (q, 2H), 2.25 (s, 3H), 1.90 (s, 3H), 1.41 (qn, 2H), 1.28-1.09 (m, 4H), 0.82 (t, 3H); LC-MS m/z 313 (multimode -).

(iii) 5-(4-(3-(Dimethylamino)propoxy)-2-methylbenzyl)-6-methyl- N^4 -pentylpyrimidine-2,4-diamine

30 The method of Example 3 using the product of step (ii) (0.1 g) and dimethylaminopropylchloride hydrochloride (0.075 g) was used to provide the title compound as a colourless solid (13 mg); ^1H NMR: 6.76 (d, 1H), 6.57 (dd, 1H), 6.47 (d, 1H), 5.97 (t, 1H), 5.63 (s,

2H), 3.91 (t, 2H), 3.52 (s, 2H), 3.22 (q, 2H), 2.34-2.27 (m, 5H), 2.12 (s, 6H), 1.90 (s, 3H), 1.79 (qn, 2H), 1.46-1.36 (m, 2H), 1.27-1.06 (m, 4H), 0.81 (t, 3H); LC-MS m/z 400.

Example 34: (R)-Methyl 2-(3-(1-(2-amino-5-(4-(3-(dimethylamino)propoxy)benzyl)-6-methylpyrimidin-4-ylamino)-3-hydroxypropyl)phenyl)acetate

5 (i) 4-((2-Amino-4-bromo-6-methylpyrimidin-5-yl)methyl)phenol and 4-((2-amino-4-chloro-6-methylpyrimidin-5-yl)methyl)phenol

A solution of BBr_3 (1 M in DCM, 15.2 mL) was added portion-wise to a stirred suspension to the product of Example 1 step (iii) (1 g) in DCM (20 mL) at 0 °C, over a period of 10 mins. under N_2 . The resulting mixture was stirred at 0°C for 1 h. The mixture was then diluted with 2M HCl (30 mL) and MeOH (10 mL) then stirred at r.t. for 30 mins. The organic phase was separated and the aqueous phase was extracted with EtOAc (2 × 50 mL). The combined organic extracts were dried and concentrated by evaporation to afford a 1:1 mixture of the subtitle compounds (0.230 g) which were used in the subsequent step without purification; 1H NMR: 6.90 (4H, d), 6.67 (4H, d), 3.89-3.79 (4H, m), 2.22 (3H, s), 2.20 (3H, s).

15 (ii) 4-Bromo-5-(4-(3-(dimethylamino)propoxy)benzyl)-6-methylpyrimidin-2-amine and 4-Chloro-5-(4-(3-(dimethylamino)propoxy)benzyl)-6-methylpyrimidin-2-amine

3-(Dimethylamino)propyl chloride hydrochloride (0.437 g) was added to a stirred suspension of the product of step (i) (0.23 g), CS_2CO_3 (2.401 g) and NaI (0.069 g) in DMF (10 mL). The resulting suspension was stirred at 80°C for 3 h., cooled, and diluted with EtOAc (20 mL). The organic phase was washed with water (3 × 30 mL), brine (30 mL) dried and concentrated by evaporation. The crude product was purified by FCC eluting with DCM then 10:2 DCM-MeOH to afford a 1:1 mixture of the subtitle compounds (0.043 g) which were used in the subsequent step without purification; 1H NMR: 7.00 (d, 4H), 6.88-6.79 (m, 4H), 3.94 (t, 4H), 3.89 (s, 2H), 3.87 (s, 2H), 2.41 (t, 4H), 2.19 (s, 18H), 1.84 (qn, 4H).

25 (iii) (E)-tert-Butyl 3-(3-(hydroxymethyl)phenyl)acrylate

A mixture of (3-bromophenyl)methanol (7.3 g), *tert*-butyl acrylate (15 g), palladium acetate (0.235g) and tri(*o*-tolyl)phosphine (1.25 g) in MeCN (80 mL) was heated at 90°C for 2 h. The solution was then cooled, concentrated by evaporation. The resulting residue was dissolved in EtOAc, washed with water, dried and concentrated by evaporation. The crude product was purified by FCC eluting with using 8:2 to 7:3 isohexane-EtOAc to give

the subtitle compound (7.8 g); ¹H NMR (CDCl₃): 7.58 (1H, d), 7.52 (1H, s), 7.45-7.33 (3H, m), 6.38 (1H, d), 4.72 (2H, s), 1.53 (9H, s).

(iv) (R)-tert-Butyl 3-(benzyl((S)-1-phenylethyl)amino)-3-(3-((tert-butyldimethylsilyloxy)methyl)phenyl)propanoate

5 A solution of butyl lithium (2.5 M in hexane, 34 mL) was added to a solution of (S)-(-)-N-benzyl- α -methylbenzylamine in THF (200 mL) at -78°C and the mixture was stirred for 45 mins. A solution of the product of step (iii) (7.8 g) in THF (20 mL) was added and stirring was continued for 3 h. Then the cooling bath was removed, NH₄Cl solution was added and the solution was allowed to warm to r.t. EtOAc and water were added, the
10 organic phase was separated, dried and concentrated to give a residue which was passed through silica gel eluting with 4:1 isohexane-EtOAc. Removal of solvent by evaporation gave a residue which was dissolved in DMF (120 mL). Imidazole (5 g) and *tert*-butyldimethylsilylchloride were added and the solution was stirred at r.t. for 2 h. EtOAc and water were then added, the organic phase was separated, dried and concentrated to give the
15 crude product which was purified by FCC eluting with 95:5 isohexane-EtOAc to give the subtitle compound (18 g); LC-MS *m/z* 560 (APCI +).

(v) (R)-3-(Benzyl((S)-1-phenylethyl)amino)-3-(3-((tert-butyldimethylsilyloxy)methyl)phenyl)propan-1-ol

The product of step (iv) (18 g) was dissolved in THF (120 mL) and a solution of LiAlH₄ (1M in THF, 45 mL) was added. The mixture was then stirred at r.t. for 4 h. and then water
20 was added. 45% NaOH solution and water were added and the mixture stirred for 1 h. The solvent was then removed by decantation to give a residue which was dissolved in diethyl ether. The organic solution was washed with brine, dried and concentrated by evaporation to give the subtitle compound (15.5 g); LC-MS *m/z* 490 (APCI +).

25 (vi) (3-((R)-1-(Benzyl((S)-1-phenylethyl)amino)-3 (methoxymethoxy)propyl)-phenyl)methanol

To a solution of the product from step (v) and DIPEA (17 mL) in DCM (160 mL) at 0°C was added chloromethyl methylether. The mixture was warmed to r.t. and stirred for 18 h. A further aliquot of chloromethyl methylether (0.4 mL) was added and the mixture further
30 stirred for 18 h. The mixture was washed with water, dried and concentrated by evaporation. The resulting residue was dissolved in THF (250 mL). Tetrabutylammonium fluoride solution (75 wt% in water, 10 mL) was added and the mixture stirred for 4 h.

Brine and EtOAc were added, the organic phase was separated, washed with brine, dried and concentrated by evaporation to give the crude product which was purified by FCC eluting with 7:3 isohexane-EtOAc to give the subtitle compound (10.9 g); ¹H NMR (CDCl₃): 7.45-7.18 (10H, m), 4.71 (2H, d), 4.42 (2H, s), 4.15-4.08 (1H, m), 3.98-3.94 (1H, m), 3.84-3.64 (2H, m), 3.28-3.22 (5H, m), 2.20-2.10 (1H, m), 1.90-1.78 (1H, m), 1.69 (1H bs), 1.16 (3H, d).

(vii) 3-((R)-1-(Benzyl((S)-1-phenylethyl)amino)-3-(methoxymethoxy)propyl)benzyl methanesulfonate

Methane sulphonyl chloride (1.912 mL) was added dropwise to a solution of the product from step (vi) (9.5 g) and triethylamine (4.8 mL) in DCM (100 mL) at 0-5°C under N₂. The resulting mixture was stirred for 1 h, then the solvent was removed to give the crude subtitle compound which was used in the next step without further purification (11.27 g); LC-MS *m/z* 498 (APCI +)

(viii) 2-(3-((R)-1-(Benzyl((S)-1-phenylethyl)amino)-3-(methoxymethoxy)propyl)-phenyl)acetonitrile

KCN (6 g) was added in one portion to the product of step (vii) (11.27 g) in DMSO (30 mL) and DMF (30 mL) and the mixture was warmed to 50°C under N₂. The resulting mixture was stirred at 50°C for 18 h then partitioned between EtOAc and water. The organic phase was separated, washed with water, dried and concentrated by evaporation to give the crude subtitle compound which was used in the next step without further purification (7.69 g); LC-MS *m/z* 429 (APCI +).

(ix) Methyl 2-(3-((R)-1-(benzyl((S)-1-phenylethyl)amino)-3-hydroxypropyl)phenyl)acetate

A solution of KOH (2.81 g) dissolved in water (10 mL) was added to a stirred solution of the product of step (viii) (7.69 g, 17.94 mmol) in EtOH (50 mL) at r.t. The mixture was stirred at reflux for 24 h. The mixture was then concentrated by evaporation and the resulting residue azeotroped with toluene. MeOH (100 mL) followed by conc. HCl (3 mL) were added to the residue and the mixture was stirred at r.t. for 3 days. The mixture was then concentrated by evaporation and the resulting residue was partitioned between EtOAc and water. The organic phase was separated, washed with water, dried and concentrated by evaporation. The crude product was purified by FCC eluting with 7:3 isohexane-EtOAc to afford the subtitle compound as an oil (2.32 g); ¹H NMR (CDCl₃): 7.43-7.19 (m, 14H); 4.14-4.08 (m, 1H); 3.96-3.92 (m, 2H); 3.70 (s, 3H); 3.66 (s, 2H); 3.62-3.53 (m, 2H); 3.41-

3.35 (m, 1H); 2.24-2.15 (m, 1H); 1.84 (br s, 1H); 1.74-1.65 (m, 1H); 1.04 (d, 3H); LC-MS m/z 418 (APCI +).

(x) (R)-methyl 2-(3-(1-amino-3-hydroxypropyl)phenyl)acetate

A suspension of the product of step (ix) (2.3 g) and Pd/C (0.9 g) in MeOH (60 mL) was stirred under a H₂ pressure of 45psi at r.t. for 24 h. The mixture was then filtered through diatomaceous earth (CeliteTM) and the solvent was evaporated to give a residue which was purified by FCC eluting with 84:16 DCM-MeOH to give the subtitle compound as an oil (480 mg); ¹H NMR: 7.26-7.07 (m, 4H); 3.89 (t, 1H); 3.64 (s, 2H); 3.61 (s, 3H); 3.47-3.37 (m, 2H); 1.71-1.60 (m, 2H).

(xi) (R)-methyl 2-(3-(1-(2-amino-5-(4-(3-(dimethylamino)propoxy)benzyl)-6-methylpyrimidin-4-ylamino)-3-hydroxypropyl)phenyl)acetate

A solution of the products of step (ii) (0.045 g) and the product of step (x) (0.107 g) in butan-1-ol (3 mL) were sealed into a microwave tube and heated to 170°C in a microwave reactor for 2.5 h. The solvent was then removed by evaporation and the resulting residue was partitioned between EtOAc (5 mL) and water (5 mL). The organic phase was separated and the aqueous phase was extracted with EtOAc (5 mL). The combined organic phases were dried and concentrated by evaporation to give a residue which was purified by RPHPLC to give the title compound as a colourless gum (11 mg); ¹H NMR: 7.20-7.13 (m, 1H), 7.10-7.00 (m, 5H), 6.82 (d, 2H), 6.41 (d, 1H), 5.60 (s, 2H), 5.36-5.26 (m, 1H), 4.52 (t, 1H), 3.94 (t, 2H), 3.78 (d, 1H), 3.69 (d, 1H), 3.60 (s, 3H), 3.57 (s, 4H), 2.37-2.31 (m, 2H), 2.14 (s, 6H), 2.02 (s, 3H), 1.91-1.77 (m, 4H); LC-MS m/z 522.

Example 35: (R)-Methyl 2-(3-(1-(2-amino-5-(4-(3-(dimethylamino)propoxy)-2-methoxybenzyl)-6-methylpyrimidin-4-ylamino)-3-hydroxypropyl)phenyl)acetate
(R)-Methyl 2-(3-(1-(2-amino-5-(4-(3-(dimethylamino)propoxy)-2-methoxybenzyl)-6-methylpyrimidin-4-ylamino)-3-hydroxypropyl)phenyl)acetate

A solution of the product of Example 11 step (v) (0.15 g) and the product of Example 34 step (x) (0.184 g) in butan-1-ol (3 mL) were sealed into a microwave tube and heated to 170°C in a microwave reactor for 2 h. The solvent was then removed by evaporation and the resulting residue was diluted with MeOH (2 mL) and conc. H₂SO₄ (0.5 mL). The mixture was then stirred at 65°C for 2 h, allowed to cool, adjusted to pH 7 with sat. NaHCO₃ and then extracted EtOAc (3 × 10 mL). The combined organic phases were dried

and concentrated by evaporation to give a crude product which was purified by RPHPLC to give the title compound as a colourless solid (43.0 mg); ¹H NMR: 7.16 (1H, dd), 7.09-7.00 (2H, m), 6.67 (1H, d), 6.55 (1H, d), 6.40 (1H, dd), 6.21 (1H, d), 5.58 (2H, s), 5.32-5.24 (1H, m), 4.47 (1H, s), 3.96 (2H, t), 3.82 (3H, s), 3.65-3.55 (9H, m), 2.34 (2H, t), 2.14 (6H, s), 2.01 (3H, s), 1.87-1.77 (4H, m); LC-MS *m/z* 552.

Example 36: 3-(4-((2-Amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxyphenoxy)propan-1-ol

(i) 4-(3-(*tert*-Butyldimethylsilyloxy)propoxy)-2-methoxybenzaldehyde

(3-Bromopropoxy)(*tert*-butyl)dimethylsilane (6.85 mL) and K₂CO₃ (4.09 g, 29.6 mmol) were added to a solution of 4-hydroxy-2-methoxybenzaldehyde (3.00 g) in DMF (30 mL) and the mixture was stirred for 14 h at r.t. Brine was added, and the mixture was then extracted twice with EtOAc. The combined organic layers were washed with water and brine, dried (MgSO₄) and concentrated. The resulting residue was purified by FCC to give the subtitle compound as colourless oil (5.97 g); ¹H NMR (CDCl₃): 10.29 (1H, s), 7.80 (1H, d), 6.55 (1H, dd), 6.45 (1H, d), 4.15 (2H, t), 3.90 (3H, s), 3.81 (2H, t), 2.00 (2H, tt), 0.89 (9H, s), 0.05 (6H, s).

(ii) 4-(3-(*tert*-Butyldimethylsilyloxy)propoxy)-2-methoxyphenyl)methanol

NaBH₄ (0.35 g) was added to a solution of the product of step (i) (5.97 g) in THF/MeOH (30 mL / 3 mL) at 0°C, and then the mixture was stirred for 1 h. The reaction was quenched with brine, and extracted twice with EtOAc. The combined organic layers were washed with brine, dried (MgSO₄) and concentrated. The residue was purified by FCC to give subtitle compound as colourless oil (5.76 g); ¹H NMR (CDCl₃): 7.14 (1H, d), 6.46 (2H, m), 4.61 (2H, s), 4.06 (2H, t), 3.85 (3H, s), 3.81 (2H, t), 2.15 (1H, br s), 1.99 (2H, tt), 0.89 (9H, s), 0.05 (6H, s).

(iii) Methyl 2-(4-(3-(*tert*-butyldimethylsilyloxy)propoxy)-2-methoxybenzyl)-3-oxobutanoate

Methanesulfonyl chloride (0.93 mL) was added to the mixture of the product from step (ii) (2.50 g) and DIPEA (2.09 mL) in THF (30 mL) at r.t. and the mixture was stirred for 2 h. The resulting solid was removed by filtration. The filtrate was concentrated *in vacuo*, and then dissolved in DMF (20 mL). Methyl acetoacetate (0.99 mL) was added to a suspension of NaH (55% oil dispersion, 0.37 g) in DMF (15 mL) at 0°C and the mixture was stirred for 15 min. The DMF solution described above and KI (1.27 g) were added to the mixture

and it was all stirred at 80°C for 4 h. The mixture was cooled to r.t. and diluted with EtOAc. The mixture was then washed with sat. NaHCO₃ and brine. The organic layer was dried (MgSO₄) and concentrated. The resulting residue was purified by FCC to give the subtitle compound as colourless oil (1.80 g); ¹H NMR (CDCl₃): 6.99 (1H, d), 6.42 (1H, d), 6.38 (1H, dd), 4.03 (2H, t), 3.89 (1H, t), 3.81 (3H, s), 3.80 (2H, t), 3.67 (3H, s), 3.09 (2H, m), 2.17 (3H, s), 1.97 (2H, tt), 0.88 (9H, s), 0.04 (6H, s).

(iv) 2-Amino-5-(4-(3-(*tert*-butyldimethylsilyloxy)propoxy)-2-methoxybenzyl)-6-methylpyrimidin-4-ol

Guanidium carbonate (0.98 g) was added to a solution of the product from step (iii) (1.78 g) in MeOH (50 mL) and the mixture was heated at 65°C for 7 h. The mixture was then cooled to r.t. and water (50 mL) was added. The resulting solid was collected by filtration and washed with EtOH/water (50 mL /50 mL), water (50 mL), EtOH (50 mL) to afford subtitle compound as a white solid (1.53 g); ¹H NMR: 6.71 (1H, d), 6.41 (1H, d), 6.37 (1H, dd), 6.32 (2H, br s), 3.97 (2H, t), 3.79 (3H, s), 3.75 (2H, t), 3.45 (2H, s), 1.92 (3H, s), 1.85 (2H, tt), 0.85 (9H, s), 0.02 (6H, s); LC-MS *m/z* 433 ESI.

(v) 2-Amino-5-(4-(3-(*tert*-butyldimethylsilyloxy)propoxy)-2-methoxybenzyl)-6-methylpyrimidin-4-yl 2,4,6-trimethylbenzenesulfonate

*N*¹,*N*¹,*N*³,*N*³-tetramethylpropane-1,3-diamine (0.88 mL) and 2,4,6-trimethylbenzene-1-sulfonyl chloride (1.15 g) were added to the solution of the product from step (iv) (1.52 g) in THF (15 mL) and the mixture was stirred at r.t. After 22 h, 0.1N HCl aq. (45 mL) was added and the mixture was then extracted twice with CHCl₃. The organic layer was dried (MgSO₄) and concentrated. The resulting residue was purified by FCC to give the subtitle compound as pale yellow oil (1.92 g); ¹H NMR (CDCl₃): 6.94 (2H, s), 6.71 (1H, d), 6.41 (1H, d), 6.33 (1H, dd), 4.72 (2H, br s), 4.02 (2H, t), 3.81 (2H, t), 3.79 (3H, s), 3.76 (2H, s), 2.61 (6H, s), 2.31 (3H, s), 2.26 (3H, s), 1.98 (2H, tt), 0.89 (9H, s), 0.05 (6H, s); LC-MS *m/z* 616 ESI.

(vi) 5-(4-(3-(*tert*-Butyldimethylsilyloxy)propoxy)-2-methoxybenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine

Trifluoroacetic acid (0.48 mL) and amylamine (1.78 mL) were added to the solution of the product from step (v) (1.90 g) in propionitrile (19 mL) and the mixture was stirred at 100°C for 3 h. The solvent was then removed by evaporation and the resulting residue was diluted with EtOAc (50 mL) and washed with 4% NH₃ solution (20 mL × 4) and brine (20

mL), then dried (MgSO₄) and concentrated. The resulting residue was purified by FCC to give the subtitle compound as pale yellow oil (1.03 g); ¹H NMR (CDCl₃): 6.82 (1H, d), 6.47 (1H, d), 6.40 (1H, dd), 5.10 (2H, br s), 4.03 (2H, t), 3.88 (3H, s), 3.79 (2H, t), 3.72 (1H, q), 3.60 (2H, s), 3.28 (2H, q), 2.36 (3H, s), 1.97 (2H, tt), 1.44 (2H, tt), 1.25 (2H, m), 1.15 (2H, m), 0.89 (9H, s), 0.86 (3H, t), 0.05 (6H, s); LC-MS *m/z* 502 ESI.

(vii) 3-(4-((2-Amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxyphenoxy)propan-1-ol

Tetrabutylammonium fluoride (1.0 M THF solution, 4.1 mL) was added to the solution of the product from step (vi) (1.03 g) in THF (6 mL) and the mixture was stirred at r.t. for 4 h. The mixture was then diluted with EtOAc (30 mL), and washed with 4% NH₃ solution (20 mL), brine (20 mL), then dried (Na₂SO₄) and concentrated. The resulting residue was purified by FCC to give the title compound as a white solid (0.51 g); ¹H NMR (CDCl₃): 6.82 (1H, d), 6.48 (1H, d), 6.38 (1H, dd), 4.87 (1H, br t), 4.69 (2H, br s), 4.10 (2H, t), 3.88 (3H, s), 3.86 (2H, t), 3.61 (2H, s), 3.28 (2H, dq), 2.32 (3H, s), 2.04 (2H, tt), 1.90 (1H, br s), 1.44 (2H, tt), 1.25 (2H, m), 1.15 (2H, m), 0.84 (3H, t); LC-MS *m/z* 388 ESI.

Example 37: 5-(2-Methoxy-4-(3-morpholinopropoxy)benzyl)-6-methyl-N⁴-pentylpyrimidine-2,4-diamine

Methanesulfonyl chloride (0.030 mL) was added to the mixture of the product from Example 36 (0.14 g) and triethylamine (0.053 mL) in THF (5 mL) at 0°C. The resulting mixture was stirred for 30 min. Sat. NaHCO₃ was then added and then the solution was extracted twice with CHCl₃. The organic layer was dried (MgSO₄) and concentrated. The resulting residue was dissolved in DMF (5 mL). Morpholine (0.33 mL) was added and the mixture was stirred at 60°C for 5 h. 4% NH₃ solution was then added and brine and the mixture was extracted twice with EtOAc. The combined organic layers were washed twice with brine, dried (Na₂SO₄) and concentrated. The resulting residue was purified by FCC to give the title compound as a white solid (0.13 g); ¹H NMR: 6.59 (1H, d), 6.52 (1H, d), 6.37 (1H, dd), 5.89 (1H, br t), 5.65 (2H, br s), 3.94 (2H, t), 3.82 (3H, s), 3.55 (4H, t), 3.51 (2H, s), 3.20 (2H, q), 2.39 (2H, t), 2.34 (4H, m), 1.98 (3H, s), 1.83 (2H, tt), 1.41 (2H, tt), 1.24 (2H, m), 1.14 (2H, m), 0.84 (3H, t); LC-MS *m/z* 457 ESI.

Example 38: 5-(2-Methoxy-4-(3-(4-methylpiperazin-1-yl)propoxy)benzyl)-6-methyl-N⁴-pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 37 using the product from Example 36 (0.14 g) as a white solid (0.13 g); ¹H NMR: 6.59 (1H, d), 6.52 (1H, d), 6.37 (1H, dd), 5.88 (1H, br t), 5.64 (2H, br s), 3.93 (2H, t), 3.82 (3H, s), 3.51 (2H, s), 3.21 (2H, q), 2.36 (2H, t), 2.29 (8H, m), 2.12 (3H, s), 1.98 (3H, s), 1.82 (2H, tt), 1.41 (2H, tt), 1.24 (2H, m), 1.14 (2H, m), 0.82 (3H, t); LC-MS *m/z* 470 ESI.

Example 39: 5-(4-(4-(Dimethylamino)butyl)-2-methoxybenzyl)-6-methyl-N⁴-pentylpyrimidine-2,4-diamine

(i) Methyl 4-(4-(*tert*-butyldimethylsilyloxy)but-1-ynyl)-2-methoxybenzoate

4-(*tert*-Butyldimethylsilyloxy)butyne (3.7 g) and methyl 4-bromo-2-methoxybenzoate (4.0 g) were dissolved in THF (30 mL purged with N₂) and CuI (0.61 g), Pd(PPh₃)₄ (1.8 g) and triethylamine (4.1 mL) were added. The mixture was then heated to 100°C for 6 h, cooled and diluted with EtOAc (10 mL). The solution was washed with 0.2N HCl (2 × 10 mL), sat. NaHCO₃ (2 × 10 mL) and brine. The organic phase was dried and concentrated by evaporation. The resulting residue was purified by FCC to give the subtitle compound as colourless oil (5.6 g); ¹H NMR: 7.61 (1H, d), 7.08 (1H, d), 6.99 (1H, dd), 3.80-3.75 (8H, m), 2.63 (2H, t), 0.87 (9H, s), 0.06 (6H, s); ESI *m/z* 349 (M+1).

(ii) Methyl 4-(4-(*tert*-butyldimethylsilyloxy)butyl)-2-methoxybenzoate

The product from step (i) (5.6 g) was dissolved in MeOH. 10% Pd/C (50% wet) (1.0 g) was added and the mixture was stirred under H₂ for 7 h at r.t. The Pd/C was filtered off and the filtrate was concentrated to give the subtitle compound as colourless oil (5.6 g); ¹H NMR: 7.56 (1H, d), 6.95 (1H, d), 6.82 (1H, dd), 3.79 (3H, s), 3.74 (3H, s), 3.58 (2H, t), 3.58 (2H, t), 1.64-1.57 (2H, m), 1.50-1.44 (2H, m), 0.83 (9H, s), 0.01 (6H, s); MS:ESI 353 (M+1).

(iii) 4-(4-(*tert*-Butyldimethylsilyloxy)butyl)-2-methoxyphenyl)methanol

The product from step (ii) (5.6 g) in THF (30 mL) was added to the suspension of LiAlH₄ (0.61 g) in THF (50 mL) and the mixture was stirred for 0.5 h at r.t. The mixture was then cooled with an ice-bath and sat. Na₂SO₄ (2 mL) was added slowly and the mixture was stirred for 2 h at r.t. The mixture was then dried (Na₂SO₄), precipitate was filtered off using diatomaceous earth (CeliteTM) and the filtrate was concentrated to give the subtitle compound as colourless oil (4.4 g); ¹H NMR: 7.22 (1H, d), 6.73-6.71 (2H, m), 4.87 (1H, t),

4.42 (2H, d), 3.73 (3H, s), 3.60-3.56 (2H, m), 2.55 (2H, t), 1.61-1.57 (2H, m), 1.50-1.43 (2H, m), 0.84 (9H, s), 0.01 (6H, s).

(iv) *tert*-Butyl(4-(4-(chloromethyl)-3-methoxyphenyl)butoxy)dimethylsilane

Methanesulfonyl chloride (54 μ L) was added to the mixture of the product from step (iii) (195 mg) and DIPEA (155 μ L) in THF (3 mL) at 0°C. After stirring for 10 mins, LiCl (42 mg) was added and the mixture was stirred for 2 h and then diluted with EtOAc (10 mL). The solution was washed with 0.2N HCl (2 $\times$ 10 mL), sat. NaHCO₃ (2 $\times$ 10 mL) and brine. The organic phase was dried and concentrated to give the subtitle compound as colourless oil (200 mg); ¹H NMR: 7.26 (1H, d), 6.84 (1H, d), 6.74 (1H, dd), 4.65 (2H, s), 3.80 (3H, s), 3.58 (2H, t), 2.57 (2H, t), 1.63-1.58 (2H, m), 1.48-1.34 (2H, m), 0.84 (9H, s), 0.00 (6H, s).

(v) methyl 2-(4-(4-(*tert*-butyldimethylsilyloxy)butyl)-2-methoxybenzyl)-3-oxobutanoate

Methyl acetoacetate (161 μ L) was added to the suspension of NaH (55% oil dispersion, 43 mg) in THF (5 mL) at 0°C and the mixture was stirred for 0.5 h. The product from step (iv) (200 mg) in THF (5 mL) and KI (83 mg) were added and the mixture was stirred at 80°C for 2h. The mixture was then cooled to r.t. and diluted with EtOAc (30 mL). The mixture was then washed with 0.1N HCl (2 $\times$ 10 mL), sat. NaHCO₃ (2 $\times$ 10 mL) and brine. The organic phase was dried and concentrated and the residue was purified by FCC to give the subtitle compound as colourless oil (200 mg); ¹H NMR: 6.93 (1H, d), 6.76 (1H, d), 6.64 (1H, dd), 3.89-3.85 (1H, m), 3.85 (3H, s), 3.62-3.55 (5H, m), 2.98-2.89 (2H, m), 2.54-2.50 (2H, m), 2.12 (3H, s), 1.59-1.56 (2H, m), 1.46-1.42 (2H, m), 0.84 (9H, s), 0.00 (6H, s); MS:ESI 423 (M+1).

(vi) 2-Amino-5-(4-(4-(*tert*-butyldimethylsilyloxy)butyl)-2-methoxybenzyl)-6-methylpyrimidin-4-ol

Guanidium carbonate (109 mg) was added to a solution of the product from step (v) (200 mg) in MeOH (5 mL) and the mixture was heated at 65°C for 12 h. The mixture was then cooled to r.t. and diluted with EtOAc (30 mL). The mixture was then washed with sat. NaHCO₃ (2 $\times$ 10 mL) and brine. The organic phase was dried and concentrated and the residue was purified by FCC to give the subtitle compound as colourless oil (147 mg); ¹H NMR: 6.73-6.69 (2H, m), 6.59 (1H, dd), 6.30 (2H, brs), 3.77 (3H, s), 3.57(2H, t), 3.37 (2H, s), 2.52-2.50 (2H, m), 2.94 (3H, s), 1.59-1.56 (2H, m), 1.46-1.42 (2H, m), 0.84 (9H, s), 0.00 (6H, s).

(vii) 2-Amino-5-(4-(4-(*tert*-butyldimethylsilyloxy)butyl)-2-methoxybenzyl)-6

methylpyrimidin-4-yl 2,4,6-trimethylbenzenesulfonate

The subtitle compound was prepared by the method of Example 35 step (v) using the product from step (vi) (142 mg) to give a colourless oil (260 mg); ¹H NMR: 7.07 (2H, s), 6.75-6.72 (3H, m), 6.61-6.98 (2H, m), 3.72 (3H, s), 3.61-3.57 (4H, m), 2.55-2.51 (2H, m), 2.42 (6H, s), 2.28 (3H, s), 2.24 (3H, s), 1.61-1.54 (2H, m), 1.53-1.42 (2H, m), 0.84 (9H, s), 0.00 (6H, s).

(viii) 5-(4-(4-(*tert*-Butyldimethylsilyloxy)butyl)-2-methoxybenzyl)-6-methyl-*N*⁴pentylpyrimidine-2,4-diamine

The subtitle compound was prepared by the method of Example 36 step (vi) using the product from step (vii) (260 mg) to give a colourless oil (101 mg); ¹H NMR: 6.78 (1H, s), 6.60 (2H, s), 6.01 (1H, br s), 5.72 (2H, br s), 3.81 (3H, s), 3.58-3.54 (4H, m), 3.25-3.17 (2H, m), 2.53-2.49 (2H, m), 1.96 (3H, s), 1.63-1.51 (2H, m), 1.50-1.37 (4H, m), 1.30-1.08 (4H, m), 0.84-0.78 (12H, m), 0.00 (6H, s); MS:ESI 501 (M+1).

(ix) 4-(4-((2-Amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxyphenyl)butan-1-ol

The subtitle compound was prepared by the method of Example 36 step (vii) using the product from step (x) (100 mg) to give a colourless oil (71 mg); ¹H NMR: 6.79 (1H, s), 6.61-6.50 (2H, m), 5.95 (1H, t), 5.64 (2H, br s), 4.36 (1H, t), 3.82 (3H, s), 3.55 (2H, s), 3.39-3.33 (2H, m), 3.22-3.17 (2H, m), 2.52-2.49 (2H, m), 1.96 (3H, s), 1.57-1.53 (2H, m), 1.42-1.37 (4H, m), 1.22-1.10 (4H, m), 0.80 (3H, t); MS:ESI 387 (M+1).

(x) 5-(4-(4-(Dimethylamino)butyl)-2-methoxybenzyl)-6-methyl-*N*⁴-pentylpyrimidine-2,4-diamine

The title compound was prepared by the method of Example 37 using the product from step (ix) to give a white solid (58 mg); ¹H NMR: 6.79 (1H, s), 6.61-6.50 (2H, m), 5.94-5.92 (1H, m), 5.63 (2H, s), 3.82 (3H, s), 3.54 (2H, s), 3.22-3.17 (2H, m), 2.52-2.49 (2H, m), 2.18-2.14 (2H, m), 2.05 (6H, s), 1.95 (3H, s), 1.55-1.49 (2H, m), 1.44-1.32 (4H, m), 1.24-1.09 (4H, m), 0.81 (3H, t); MS:ESI 414 (M+1).

Example 40: (S)-2-(2-Amino-5-(4-(hydroxymethyl)-2-methoxybenzyl)-6-methylpyrimidin-4-ylamino)pentan-1-ol

(i) (S)-Methyl 4-((2-amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)-methyl)-3-methoxybenzoate

(S)-2-Aminopentan-1-ol (0.481 g) was added to a suspension of the product from Example 12 step (iii) (0.5 g) in dioxane (5 mL) and the mixture was heated in a CEM microwave at 170°C for 9 h. The mixture was then cooled, the solvent was removed by evaporation. The residue was purified by FCC using 5% MeOH in DCM to give the subtitle compound
5 (0.250 g) as a orange gum; ¹H NMR: 7.53–7.42 (2H, m), 6.89 (1H, d), 5.75 (2H, d), 5.58 (1H, d), 4.61–4.54 (1H, m), 4.17–4.08 (1H, m), 3.92 (3H, s), 3.83 (3H, s), 3.69 (2H, d), 3.28–3.23 (m, 1H), 2.00 (3H, d), 1.53–1.40 (m, 1H), 1.35–1.19 (m, 2H), 1.16–1.02 (m, 2H), 0.77 (3H, t); LC-MS *m/z* 389.

10 (ii) (S)-4-((2-Amino-4-(1-hydroxypentan-2-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzoic acid


The product from step (i) (220 mg) was dissolved in THF (3 mL) and water (3 mL) and LiOH solution (3 M, 0.944 mL) was then added. The mixture was then heated in a CEM microwave for 6 h at 120°C. The solvent was then removed by evaporation and the resulting residue was dissolved in water and acidified with 2 M HCl to pH7. The resulting
15 solid precipitate was filtered off and dried under high vacuum overnight to give subtitle compound (90 mg); ¹H NMR: 7.53–7.42 (2H, m), 6.92 (1H, d), 6.61 (2H, d), 4.21 (1H, d), 3.91 (3H, d), 3.75 (2H, s), 2.09 (3H, s), 1.53–1.42 (1H, m), 1.40–1.20 (2H, m), 1.09 (2H, q), 0.78 (3H, t); LC-MS *m/z* 375.

20 (iii) (S)-2-(2-Amino-5-(4-(hydroxymethyl)-2-methoxybenzyl)-6-methylpyrimidin-4-ylamino)pentan-1-ol

Borane-THF complex (1 M, 3 mL, 3.00 mmol) was added to the product of step (ii) (85 mg) and the mixture was heated to 80°C for 2 h. MeOH was then carefully added and the mixture was heated to 80°C for 1 h. The solvent was then removed by evaporation and the resulting residue was dissolved in MeOH and loaded onto a SCX cartridge. The cartridge
25 was washed with MeOH and eluted with a solution of 0.7 M NH₃ in MeOH. The solvents were evaporated to give title compound as a colourless gum (40 mg); ¹H NMR: 6.94 (1H, s), 6.74 (2H, q), 5.66 (2H, s), 5.48 (1H, t), 5.14 (1H, s), 4.59 (1H, s), 4.45 (2H, s), 4.15–4.04 (1H, m), 3.84 (3H, d), 3.59 (2H, d), 3.25 (1H, dd), 2.03 (3H, s), 1.54–1.44 (1H, m), 1.32–1.23 (2H, m), 1.11 (2H, m), 0.81–0.76 (3H, t); LC-MS *m/z* 361.

CLAIMS

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

**(I)**

Wherein:

X represents $-\text{CH}_2-$, $-\text{NR}^8-$, $-\text{O}-$ or $-\text{S}(\text{O})_n-$;

R¹ represents C_{1-6} alkyl, C_{2-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy or hydroxy C_{1-6} alkoxy C_{1-6} alkyl;

R² represents hydrogen, C_{1-6} alkyl or phenyl wherein said phenyl is optionally substituted with 1, 2 or 3 substituents selected from R^6 ;

R³ represents C_{1-6} alkyl, C_{1-6} alkoxy or $-\text{S}-\text{C}_{1-6}$ alkyl;

R⁴ represents hydrogen, halogen, C_{1-6} alkyl or C_{1-6} alkoxy;

L¹ represents a direct bond, $-(\text{CR}^9\text{R}^{10})_m-$, $-\text{CH}=\text{CH}-(\text{CR}^9\text{R}^{10})_q-$, $-\text{C}\equiv\text{C}-(\text{CR}^9\text{R}^{10})_q-$, $-\text{O}-(\text{CR}^9\text{R}^{10})_q-$, $-\text{C}(\text{O})-\text{O}-(\text{CR}^9\text{R}^{10})_q-$ or $-\text{O}-(\text{CH}_2)_q-\text{NR}^8-(\text{CH}_2)_q-$;

R⁵ represents methyl, hydroxy, $-\text{NR}^{11}\text{R}^{12}$, C_{3-6} cycloalkyl, phenyl or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and heterocyclic rings are optionally substituted with 1, 2 or 3 substituents selected from R^7 ;

R⁶ represents C_{1-6} alkyl, fluoro C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, halogen, cyano, $-\text{S}(\text{O})_n-\text{C}_{1-6}$ alkyl or $-\text{CH}_2-\text{C}(\text{O})-\text{O}-\text{C}_{1-6}$ alkyl;

R⁷ represents C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, hydroxy, hydroxy C_{1-6} alkyl or $-(\text{CH}_2)_q-\text{NR}^{11}\text{R}^{12}$;

R⁸ represents hydrogen or C_{1-6} alkyl;

R⁹ and **R¹⁰**, identically or differently on each occurrence, represents hydrogen or methyl;

R¹¹ and **R¹²** independently represent hydrogen, C_{1-4} alkyl or C_{1-4} alkoxy C_{2-4} alkyl;

m represents 1, 2, 3, 4, 5 or 6;

n represents 0, 1 or 2; and

q represents 0, 1, 2, 3, 4, 5 or 6;

with the proviso that the compound of Formula (**I**) is other than:

[3-(2-amino-4-methyl-6-pentylamino-pyrimidin-5-ylmethyl)]-benzoic acid ethyl ester;

5 methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxybenzoate;
or

methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-fluorobenzoate.

2. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof,
10 wherein **X** represents -CH₂-.

3. A compound according to Claim 1 or Claim 2, or a pharmaceutically acceptable salt thereof, wherein **R**¹ represents C₁₋₆alkyl.

15 4. A compound according to any one of Claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein **R**² represents hydrogen.

5. A compound according to any one of Claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein **R**² represents phenyl wherein said phenyl is optionally
20 substituted with 1, 2 or 3 substituents selected from R⁶.

6. A compound according to any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein **R**³ represents methyl.

25 7. A compound according to any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein **R**⁴ represents C₁₋₆alkoxy.

8. A compound according to any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein **R**⁴ represents hydrogen.

9. A compound according to any one of Claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R^4 is bonded at the ortho position of the phenyl ring relative to linkage $-X-$.

5 10. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein q represents 1, 2 or 3.

11. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein q represents 2 or 3.

10

12. A compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein L^1 represents $-(CR^9R^{10})_m-$, $-CH=CH-(CR^9R^{10})_q-$ or $-C\equiv C-(CR^9R^{10})_q-$

15 13. A compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein L^1 represents $-O-(CR^9R^{10})_q-$.

14. A compound according to any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein L^1 is bonded at the para position of the phenyl ring relative
20 to linkage $-X-$.

15. A compound according to any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein L^1 is bonded at the meta position of the phenyl ring relative to linkage $-X-$.

25

16. A compound according to any one of Claims 1 to 8 or 10 to 13, or a pharmaceutically acceptable salt thereof, wherein L^1 is bonded at the ortho position of the phenyl ring relative to linkage $-X-$.

30 17. A compound according to any one of Claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R^5 represents $NR^{11}R^{12}$ or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected

from O, N or S wherein said heterocyclic ring is optionally substituted with 1, 2 or 3 substituents selected from R⁷.

18. A compound according to any one of Claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein **R**⁵ represents NR¹¹R¹² and R¹¹ and R¹² both represent methyl.

19. A pharmaceutical composition which comprises a compound according to any one of Claims 1 to 18, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.

20. A compound according to any one of Claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use as a medicament.

21. A compound according to any one of Claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

22. Use of a compound according to any one of Claims 1 to 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer.

23. A method of treating cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of Claims 1 to 18.

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2010/050825

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D239/49 C07D401/12 C07D403/12 C07D413/12 A61K31/505
A61K31/5377 A61P35/00

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99/50249 A2 (DU PONT PHARM CO [US]) 7 October 1999 (1999-10-07) page 1, line 5 - line 16; examples A-1091 - A-1104	1-23
A	US 2005/054590 A1 (AVERETT DEVRON R [US]) 10 March 2005 (2005-03-10) paragraphs [0001], [0048]; examples 3-5	1-23
X,P	WO 2009/067081 A1 (ASTRAZENECA AB [SE]; DAINIPPON SUMITOMO PHARMA CO [JP]; BENNETT NICHOL) 28 May 2009 (2009-05-28) page 1, line 28 - line 30; claim 1; examples 20(iv),21(v),22(v),34(v),40(v),89(ii),89(i ii)	1-23

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 July 2010

Date of mailing of the international search report

06/08/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Mooren, Nicolai

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2010/050825

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9950249	A2	07-10-1999	AU 3213799 A	18-10-1999
			CA 2333927 A1	07-10-1999
			EP 1054871 A2	29-11-2000
			JP 2003504301 T	04-02-2003
US 2005054590	A1	10-03-2005	US 2009298863 A1	03-12-2009
WO 2009067081	A1	28-05-2009	AR 069412 A1	20-01-2010
			AU 2008326863 A1	28-05-2009
			CA 2704214 A1	28-05-2009
			PE 12362009 A1	16-09-2009
			US 2009209524 A1	20-08-2009
			UY 31481 A1	17-07-2009